Introduction {#s1}
============

*Toxoplasma gondii (T. gondii)*, an obligate intracellular, parasitic protozoan, is the etiologic agent of toxoplasmosis. About 30--50% of the world population is infected with the parasite, and it is the most prevalent infection among humans (Tenter et al., [@B139]; Flegr et al., [@B53]). Worldwide, over 1 billion people are estimated to be infected with *T. gondii* (Hoffmann et al., [@B64]). Its prevalence in some countries is high (e.g., Brazil, 77.5%; Sao Tome and Principe, 75.2%; Iran, 63.9%; Colombia, 63.5%; and Cuba, 61.8%) (Pappas et al., [@B112]). The annual incidence of congenital toxoplasmosis was estimated to be 190,100 cases globally (Torgerson and Mastroiacovo, [@B142]).

In the United States, the Centers for Disease Control and Prevention (CDC) reported that 22.5% of the population 12 years and older have been infected with *Toxoplasma* with 1.1 million new infections each year, making it the second most common cause of deaths due to foodborne diseases (an estimated 327 deaths) and the fourth leading cause of hospitalizations attributable to foodborne illness (an estimated 4428 hospitalizations). Also, an estimated 400--4000 infants are born with congenital toxoplasmosis in the United States each year (Jones et al., [@B69]).

*T. gondii* has three infectious stages of sporozoites (in oocysts), tachyzoites (rapidly multiplying form), and bradyzoites (tissue cyst form). Among them, tachyzoites are responsible for clinical manifestations and the acute phase of the disease. They are susceptible to the immune response of the host and to drug action. The resistant cyst form of the parasite is resistant to both the immune system and drugs (Hill and Dubey, [@B63]).

Acute toxoplasmosis in healthy individuals is usually subclinical and asymptomatic, but may lead to chronic infection. However, toxoplasmosis can lead to great morbidity and mortality rates in imunocompromised or congenitally infected individuals (Dubey and Jones, [@B44]; Ahmadpour et al., [@B4]). In AIDS patients, presence of the parasite causes necrotizing encephalitis and focal cerebral lesions in the central nervous system (CNS) from primary or recrudescent infection. In immunocompetent patients, latent toxoplasmosis occurs with the formation of cysts principally in the CNS (Martins-Duarte et al., [@B93]).

In the recent years, the development of well-tolerated and safe specific immunoprophylaxis against toxoplasmosis is a highly valuable goal for global disease control (Lim and Othman, [@B85]). Immunotherapeutics strategies for improving toxoplasmosis control could either be a vaccine which would induce strong protective immunity against toxoplasmosis, or passive immunization in cases of disease recrudescence. In the last few years, much progress has been made in vaccine research on DNA vaccination, protein vaccination, live attenuated vaccinations, and heterologous vaccination; while there were few candidates on passive immunization. New vaccine candidates have been tested, including in particular proteins from *T. gondii* ROP, MIC, and GRA organelles, multi-antigen vaccines, novel adjuvants but until now the researches could not access to a proper vaccine for prevention of toxoplasmosis in human (Zhang et al., [@B153], [@B154]).

The recommended drugs for treatment or prophylaxis of toxoplasmosis are pyrimethamine and sulfadiazine. Unfortunately, these drugs have side effects such as neutropenia, severe drop of platelet count, thrombocytopenia, leucopenia, elevation in serum creatinine and serum liver enzymes, hematological abnormalities, and hypersensitivity reactions (Bosch-Driessen et al., [@B20]; Silveira et al., [@B129]; Schmidt et al., [@B125]). In addition, other drugs, such as azithromycin, clarithromycin, spiramycin, atovaquone, dapsone, and cotrimoxazole (trimethoprim-sulfamethoxazole), have been used for clinical toxoplasmosis. However, these drugs are poorly tolerated and have no effect on the bradyzoite form (Araujo and Remington, [@B9]; Petersen and Schmidt, [@B114]; Serranti et al., [@B126]).

In a clinical trial, 24% of sera positive women treated with spiramycin and pyrimethamine plus sulfadoxine combination delivered *Toxoplasma* infected infants in France (Bessières et al., [@B18]). Spiramycin monotherapy can be effective during the early stage of pregnancy to prevent prenatal transmission (Julliac et al., [@B70]). More than 50% of patients treated with spiramycin retained *T. gondii* DNA in blood and remained infected (Habib, [@B62]).

In recent years, studies have focused on finding safe drugs with novel mechanisms of action against *T. gondii*. Accordingly, there is an urgent need to evaluate new drugs based on novel and innovative therapeutic strategies against *T. gondii* that are both efficacious and nontoxic for humans (Rodriguez and Szajnman, [@B121]; Vanagas et al., [@B143]; Angel et al., [@B7]). Therefore, the goal of the present systematic review was to retrieve published studies related to *in vitro* and *in vivo* evaluation of drugs and compounds for the treatment of toxoplasmosis (2006--2016) in order to prepare comprehensive data for designing more accurate investigations in future.

Methodology {#s2}
===========

This review followed the preferred reporting items for systematic reviews (PRISMA) guidelines (Moher et al., [@B98]).

Literature search, study selection, and data extraction
-------------------------------------------------------

English databases, including PubMed, Science Direct, Scopus, Google Scholar, ISI Web of Science, and EBSCO, were systematically searched for papers on *in vitro* and *in vivo* evaluation of anti-*Toxoplasma* activities of drugs and compounds, published worldwide, from 2006 to 2016. The keywords included were: "Toxoplasmosis," "*T. gondii*," "Anti-*Toxoplasma*," "Drug," "Anticoccidial," "Treatment," "*In vitro*," "*In vivo*," and "Compound."

Papers written in English were selected. Gray literature and abstracts of articles which were published in congresses were not explored. In addition, in order to avoid missing any articles, whole references of the papers were meticulously hand-searched. Among English articles found with the mentioned strategies, full text papers that used laboratory method both *in vitro* and *in vivo* were included.

Also, studies with at least one of the following criteria were excluded: (1) studies that were not relevant; (2) articles not available in English; (3) studies on treatments for ocular infection; (4) articles that were of review or descriptive study type; (5) articles which contained no eligible data; (6) case series reports; (7) the data were duplicated from other studies or we were unable to obtain them; (8) those that were on efficacy of anti-*T. gondii* medicines in humans; and (9) any drug with an IC~50~ value \> 10 μM.

Data collection
---------------

All the experimental studies that were carried out to evaluate the efficacy of either drugs or compounds against *T. gondii* both *in vitro* and *in vivo* were included, and replicates were excluded. The inclusion criteria for selection of *in vitro* studies were important information about medication used for the experiments, type of cells used for culture, identification of the *Toxoplasma* strain, laboratory methods used for assessing drug activities, and main results comprising of the 50% inhibitory concentration (IC~50~). We reported *in vivo* studies used animal models, *Toxoplasma* strain, route of infection, the treatment schedule (dosage, route of administration, duration of treatment), the criteria for assessing drug activity (mainly survival for acute toxoplasmosis, histology, and brain cyst burdens for chronic infection), and the main results.

Results {#s3}
=======

Analysis of the included literature
-----------------------------------

A total of 118 papers (83 studies *in vitro*, 59 *in vivo*, 27 both *in vitro* and *in vivo*) published from 2006 to 2016, were included in the systematic review. Figure [1](#F1){ref-type="fig"} briefly shows the search process in this systematic review article.

![**The PRISMA flow diagram of the search strategy, study selection, and data management procedure of ***in vitro*** and ***in vivo*** activities of anti***-Toxoplasma*** drugs and compounds (2006--2016)**.](fmicb-08-00025-g0001){#F1}

Mechanisms of action
--------------------

In the current systematic review, 80 clinically available drugs (Table [1](#T1){ref-type="table"}) and several new compounds with more than 39 pathways/ mechanisms of action were evaluated against *T. gondii* in both *in vitro* and *in vivo* studies. Several target based drug screens were also identified against *T. gondii* include mitochondrial electron transport chain, calcium-dependent protein kinase 1, type II fatty acid synthesis, DNA synthesis, DNA replication, etc. (Table [2](#T2){ref-type="table"}). Also, drugs/compounds with known mechanisms of action on life stages of *T. gondii* are shown in Figure [2](#F2){ref-type="fig"}. Our collective data indicated that many of the drugs/ compounds evaluated against *T. gondii* act on the apicoplast. Therefore, the apicoplast represents as a potential drug target for new chemotherapy.

###### 

**Clinically available drugs/compounds evaluated against ***T. gondii in vitro*** and ***in vivo*** studies**.

  **Common clinical uses**                            **Drugs/compounds**                       **References**
  --------------------------------------------------- ----------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antiprotozoal agents                                Bisphosphonates                           Baramee et al., [@B14]; Ferreira et al., [@B52]; Rajapakse et al., [@B118]; Strobl et al., [@B132]; Leepin et al., [@B80]; Shubar et al., [@B128]; Liesen et al., [@B84]; Aquino et al., [@B8]; Franco et al., [@B56]; Martins-Duarte et al., [@B92]; Chew et al., [@B28]; Asgari et al., [@B10]; Bilgin et al., [@B19]; Gomes et al., [@B60]; Gaafar et al., [@B57]; da Silva et al., [@B34]; El-Zawawy et al., [@B48],[@B49]
                                                      Diamidine analogs                         
                                                      Spiramycin (Rovamycin)                    
                                                      Thiosemicarbazides                        
                                                      4-thiazolidinones                         
                                                      1,3,4-thiadiazoles                        
                                                      Naphthalene-sulfonyl-indole               
                                                      Thiosemicarbazone                         
                                                      Phenylsemicarbazone                       
                                                      Ivermectin                                
                                                      Silver nanoparticles                      
                                                      Novel ferrocenic atovaquone derivatives   
                                                      Triclosan                                 
                                                      Triclosan liposomal nanoparticles         
                                                      Metronidazole                             
                                                      1,25(OH)2D3                               
                                                      Naphthoquinone                            
                                                      PHNQ6[^a^](#TN1){ref-type="table-fn"}     
                                                      Novel azasterols                          
                                                      Apicidin                                  
  Antimalarial agents                                 Pyrimethamine                             Meneceur et al., [@B96]; Mui et al., [@B105]; Doggett et al., [@B41]; Zhou et al., [@B155]; Jain et al., [@B68]
                                                      Atovaquone                                
                                                      Triazine JPC-2067-B                       
                                                      Spiroindolone                             
                                                      Endochin-like quinolones                  
                                                      Halofuginone                              
  Antibacterial agents                                Sulfadiazine                              Meneceur et al., [@B96]; Costa et al., [@B32]; Barbosa et al., [@B15]; Payne et al., [@B113]; Castro-Filice et al., [@B25]; Gaafar et al., [@B57]; Martins-Duarte et al., [@B89]
                                                      Azithromycin                              
                                                      Enrofloxacin                              
                                                      Fusidic acid                              
                                                      Ciprofloxacin                             
                                                      Chitosan                                  
  Antiretroviral agents                               Atazanavir                                Monzote et al., [@B104]
                                                      Fosamprenavir                             
                                                      Indinavir                                 
                                                      Nelfinavir                                
                                                      Ritonavir                                 
                                                      Saquinavir                                
  Anticoccidial agents                                NPPP[^b^](#TN2){ref-type="table-fn"}      Kul et al., [@B78]; Choi et al., [@B30]; Oz, [@B109],[@B110]
                                                      Diclazuril                                
                                                      Toltrazuril                               
  Antihelminthic agents                               Niclosamide                               Fomovska et al., [@B54]; Galván-Ramírez et al., [@B58]
                                                      Nitazoxanide                              
  Antifungal agents                                   Itraconazole                              Martins-Duarte Edos et al., [@B87]; Martins-Duarte et al., [@B91], [@B88]; Gaafar et al., [@B57]
                                                      Fluconazole                               
                                                      Chitosan                                  
  Anticancer agents                                   SAHA[^c^](#TN3){ref-type="table-fn"}      Strobl et al., [@B132]; Portes Jde et al., [@B116]; Leyke et al., [@B81]; Barna et al., [@B16]; Kadri et al., [@B71]; de Lima et al., [@B36]; Eissa et al., [@B47]; Opsenica et al., [@B108]; Dittmar et al., [@B40]
                                                      Pterocarpanquinone                        
                                                      Ruthenium complexes                       
                                                      Quinoline derivatives 4-aminoquinoline    
                                                      4-piperazinylquinoline analogs            
                                                      Miltefosine                               
                                                      Tetraoxanes                               
                                                      Gefitinib                                 
                                                      3-bromopyruvate                           
                                                      Tamoxifen                                 
  Immunosuppressants agents                           Auranofin                                 Ghaffarifar et al., [@B59]; Wei et al., [@B145]; Andrade et al., [@B6]; Ihara and Nishikawa, [@B66]
                                                      Am80                                      
                                                      Betamethasone                             
                                                      Pyridinylimidazole                        
                                                      Imidazopyrimidine                         
  Immunomodulators agents                             Rolipram                                  Afifi and Al-Rabia, [@B2]
  Immunoregulatory agents                             Levamisole                                Köksal et al., [@B76]
  Antipsychotic agents                                Aripiprazole                              Saraei et al., [@B124]
  Antioxidant agents                                  Resveratrol                               Bottari et al., [@B22]
  Antischizophrenic agents                            Haloperidol                               Goodwin et al., [@B61]; Fond et al., [@B55]; Saraei et al., [@B123]
                                                      Clozapine                                 
                                                      Fluphenazine                              
                                                      Trifluoperazine                           
                                                      Thioridazine                              
                                                      Amisulpride                               
                                                      Cyamemazine                               
                                                      Levomepromazine                           
                                                      Loxapine                                  
                                                      Olanzapine                                
                                                      Risperidone                               
                                                      Tiapride                                  
  Moodstabilizing agents                              Valproate                                 Fond et al., [@B55]
  Anti hypertensive agents                            Guanabenz                                 Benmerzouga et al., [@B17]
  Anti hypertensive and irregular heart rate agents   Propranolol                               Montazeri et al., [@B101], [@B102]

*2-hydroxy-3-(1′-propen-3-phenyl)-1,4-naphthoquinone*.

*(4-nitrophenoxy) phenyl\] propane one*.

*Suberoylanilide hydroxamic acid*.

###### 

**Drugs/compounds with pathways/ mechanisms of action against ***T. gondii*****.

  **Pathway/mechanism of action**                                         **Drugs/compounds**                                                                          **References**
  ----------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Electron transport chain                                                PHNQ6[^\*^](#TN4){ref-type="table-fn"}[^a^](#TN5){ref-type="table-fn"}                       Baramee et al., [@B14]; Ferreira et al., [@B52], [@B51]; Saleh et al., [@B122]; Meneceur et al., [@B96]; Bajohr et al., [@B13]; Doggett et al., [@B41]; Kul et al., [@B78]; de Lima et al., [@B36]
                                                                          HDQ[^\*^](#TN4){ref-type="table-fn"}[^b^](#TN6){ref-type="table-fn"}                         
                                                                          Atovaquone[^\*^](#TN4){ref-type="table-fn"}                                                  
                                                                          Endochin-like quinolones[^\*^](#TN4){ref-type="table-fn"}                                    
                                                                          Ferrocenic atovaquone derivatives                                                            
                                                                          Naphthoquinones                                                                              
                                                                          Toltrazuril                                                                                  
                                                                          3-Bromopyruvate                                                                              
  Sterol biosynthesis                                                     Novel quinuclidine (ER119884, E5700)                                                         Martins-Duarte et al., [@B93]
  Synthesis of cholesterol                                                Am80[^\*^](#TN4){ref-type="table-fn"}                                                        Ihara and Nishikawa, [@B66]
  Antifolate                                                              Pyrimethamine[^\*^](#TN4){ref-type="table-fn"}                                               Meneceur et al., [@B96]; Mui et al., [@B105]; Martins-Duarte et al., [@B88]
                                                                          Sulfadiazine[^\*^](#TN4){ref-type="table-fn"}                                                
                                                                          Dihydrotriazine[^\*^](#TN4){ref-type="table-fn"}                                             
                                                                          (JPC-2067-B, JPC-2056)                                                                       
  Calcium-dependent protein kinase 1                                      1 NM-PP1[^\*^](#TN4){ref-type="table-fn"}                                                    Sugi et al., [@B134]; Doggett et al., [@B42]; Moine et al., [@B100]; Vidadala et al., [@B144]
                                                                          Bumped Kinase Inhibitor 1294[^\*^](#TN4){ref-type="table-fn"}                                
                                                                          Imidazo \[1,2-b\] pyridazines[^\*^](#TN4){ref-type="table-fn"}                               
                                                                          Compound 32[^\*^](#TN4){ref-type="table-fn"}                                                 
  Human mitogen-activated protein kinase                                  Pyridinylimidazole[^\*^](#TN4){ref-type="table-fn"}                                          Wei et al., [@B145]
                                                                          Imidazopyrimidine[^\*^](#TN4){ref-type="table-fn"}                                           
  Nucleoside triphosphate hydrolase (NTPase)                              2-(Naphthalene-2-γlthiol)-1H indole[^\*^](#TN4){ref-type="table-fn"}                         Asgari et al., [@B10], [@B11]
  Isoprenoid pathway                                                      2- alkylaminoethyl- 1,1- bisphosphonic acids[^\*^](#TN4){ref-type="table-fn"}                Shubar et al., [@B128]; Szajnman et al., [@B138]; Li et al., [@B82]
                                                                          Newly synthesized bisphosphonates[^\*^](#TN4){ref-type="table-fn"}                           
                                                                          Atorvastatin[^\*^](#TN4){ref-type="table-fn"}                                                
  Type II fatty acid synthesis                                            Thiolactomycin[^\*^](#TN4){ref-type="table-fn"}                                              Martins-Duarte et al., [@B90]; Tipparaju et al., [@B141]; El-Zawawy et al., [@B48],[@B49]
                                                                          53 novel compounds[^\*^](#TN4){ref-type="table-fn"}                                          
                                                                          Inhibitors of enoyl reductase                                                                
                                                                          Triclosan and triclosan liposomal[^\*^](#TN4){ref-type="table-fn"}                           
  Protein synthesis                                                       Azithromycin[^\*^](#TN4){ref-type="table-fn"}                                                Costa et al., [@B32]; Franco et al., [@B56]; Chew et al., [@B28]; Zhou et al., [@B155]; Palencia et al., [@B111]
                                                                          Spiramycin[^\*^](#TN4){ref-type="table-fn"}                                                  
                                                                          Spiroindolone                                                                                
                                                                          3-aminomethyl benzoxaborole (AN6426)                                                         
  Disappearance of the Apicoplast                                         Quinoline derivatives[^\*^](#TN4){ref-type="table-fn"}                                       Smith et al., [@B130]; Kadri et al., [@B71]
                                                                          (MC1626, quinoline, 8-hydroquinoline and B23)                                                
  Histone deacetylase enzyme                                              SAHA[^\*^](#TN4){ref-type="table-fn"}[^c^](#TN7){ref-type="table-fn"}                        Strobl et al., [@B132]; Maubon et al., [@B94]; Kropf et al., [@B77]
                                                                          SBHA[^\*^](#TN4){ref-type="table-fn"}[^d^](#TN8){ref-type="table-fn"}                        
                                                                          Scriptaid[^\*^](#TN4){ref-type="table-fn"}                                                   
                                                                          Trichostatin A[^\*^](#TN4){ref-type="table-fn"}                                              
                                                                          Di-cationic pentamidine-analog[^\*^](#TN4){ref-type="table-fn"}                              
                                                                          FR235222, FR235222 derivative[^\*^](#TN4){ref-type="table-fn"}                               
  DNA synthesis                                                           Metronidazole[^\*^](#TN4){ref-type="table-fn"}                                               Liesen et al., [@B84]; Chew et al., [@B28]; Gomes et al., [@B60]
                                                                          Phenylsemicarbazone[^\*^](#TN4){ref-type="table-fn"}                                         
                                                                          Phenylthiosemicarbazones[^\*^](#TN4){ref-type="table-fn"}                                    
                                                                          Thiosemicarbazides[^\*^](#TN4){ref-type="table-fn"}                                          
                                                                          4-Thiazolidinones[^\*^](#TN4){ref-type="table-fn"}                                           
                                                                          1,3,4-thiadiazoles[^\*^](#TN4){ref-type="table-fn"}                                          
  Cyclic AMP signaling pathways                                           Rolipram[^\*^](#TN4){ref-type="table-fn"}                                                    Afifi et al., [@B3]; Afifi and Al-Rabia, [@B2]
  Post-translational modification by N-linked glycosylation of proteins   Tunicamycin[^\*^](#TN4){ref-type="table-fn"}                                                 Luk et al., [@B86]
  Membrane permeability                                                   Novel diamidine analog[^\*^](#TN4){ref-type="table-fn"}                                      Leepin et al., [@B80]
  Microfilament functional                                                Cromolyn sodium                                                                              Endeshaw et al., [@B50]; Rezaei et al., [@B119]; Montazeri et al., [@B101], [@B102]
                                                                          Ketotifen                                                                                    
                                                                          Propranolol                                                                                  
                                                                          Oryzalin analogs                                                                             
  Micronemal secretion pathway, cysteine protease                         Peptidyl vinyl sulfone compounds[^\*^](#TN4){ref-type="table-fn"} **(**LHVS and ZL3VS**)**   Teo et al., [@B140]
  Immuno-regulatory                                                       Levamisole[^\*^](#TN4){ref-type="table-fn"}                                                  Köksal et al., [@B76]
  Translational control                                                   Guanabenz[^\*^](#TN4){ref-type="table-fn"}                                                   Payne et al., [@B113]; Benmerzouga et al., [@B17]; Jain et al., [@B68]
                                                                          Fusidic acid                                                                                 
                                                                          Halofuginone[^\*^](#TN4){ref-type="table-fn"}                                                
  DNA gyrase activity, transcription                                      Enrofloxacin                                                                                 Barbosa et al., [@B15]; Martins-Duarte et al., [@B89]
                                                                          Ciprofloxacin derivatives[^\*^](#TN4){ref-type="table-fn"}                                   
  Thioredoxin reductase                                                   Auranofin                                                                                    Andrade et al., [@B6]
  Topoisomerases I and II HSP90 protein                                   Harmane, norharmane, and harmine                                                             Alomar et al., [@B5]
  Metabolism of neurotransmitters in the brain                            Resveratrol                                                                                  Bottari et al., [@B22]
  Effect on the liver biochemical parameters                              ATT-5126 and KH-0562                                                                         Choi et al., [@B30]
  Vascular ATP synthase subunit C and/or methyltransferase                NPPP                                                                                         Choi et al., [@B29]
  Sterol biosynthesis enzyme-sterol methyl transferase.                   22, 26-azasterol and 24, 25-(R, S)- epiminolanosterol                                        Martins-Duarte et al., [@B92]
  Downregulates expression of serine/threonine protein phosphatase        Diclazuril                                                                                   Oz, [@B109],[@B110]
  Ergosterol synthesis                                                    Fluconazole                                                                                  Martins-Duarte Edos et al., [@B87]; Martins-Duarte et al., [@B88]
                                                                          Itraconazole                                                                                 
  Interruption of mitosis                                                 Trifluralin                                                                                  Wiengcharoen et al., [@B147]
  Oxidative phosphorylation                                               Niclosamide                                                                                  Fomovska et al., [@B54]
  Apocynin-dependent pathway                                              NSC3852                                                                                      Strobl et al., [@B133]
  Phospholipid metabolism                                                 Miltefosine                                                                                  Eissa et al., [@B47]
  Quinone oxidoreductase expression                                       Nitaxozanide                                                                                 Galván-Ramírez et al., [@B58]
  Kinase inhibitors                                                       Small-molecules                                                                              Kamau et al., [@B72]
  Tyrosine kinase                                                         Gefitinib                                                                                    Yang et al., [@B149]
                                                                          Crizotinib                                                                                   
  Adenosine kinase in the purine salvage pathways                         N6-benzyladenosine analog[^\*^](#TN4){ref-type="table-fn"}                                   Kim et al., [@B75]; Szajnman et al., [@B138]
  Purine nucleoside phosphorylase                                         3-(thiophen-2-yl)-1,2,4-triazole-5-thione                                                    Dzitko et al., [@B46]
  Damage on the microneme proteins                                        7-nitroquinoxalin-2-ones (VAM2-2)                                                            Fernández et al., [@B120]

*Drugs/compounds with known pathway/mechanisms of action gainst T. gondii*.

*2-hydroxy-3-(1′-propen-3-phenyl)-1,4-naphthoquinone*.

*1-hydroxy-2-dodecyl-4 (1H) quinolone*.

*Suberoylanilide hydroxamic acid*.

*Suberic bishydroxamic acid*.

![**Drugs/compounds with known mechanisms of action on life stages of ***T. gondii, tachyzoites (T), and bradyzoites*** (B)**. 1, apical end; 2, Cell membrane; 3, microneme; 4, cytosol; 5, endoplasmic reticulum; 6, core; 7, mitochondria; 8, apicoplast.](fmicb-08-00025-g0002){#F2}

The investigated strains
------------------------

*T. gondii* has three main clonal lineages in population structure; type I (including a highly virulent RH strain), Type II (including ME49 and PRU, avirulent strains), and Type III (including avirulent strains like NED), which is correlated with virulence expression in mice (Howe and Sibley, [@B65]).

*In vitro* and *in vivo* screening methods were used of type I *T. gondii* (mostly RH strain; 76 studies *in vitro*, and 36 *in vivo*). Because type I RH strain is highly virulent in mice, causing 100% mortality, but types II and III are relatively less virulent. Although in some studies, ME49 (7 studies *in vitro*, and 17 *in vivo*), Prugniaud, EGS, and VEG strains were used, which showed that the outcome of infections depends on the challenge dose and on the genotype of the host (Szabo and Finney, [@B136]). Details about the investigated strains *in vitro* and *in vivo* are shown in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, respectively.

###### 

**Summary of ***in vitro*** studies evaluated the anti-***Toxoplasma*** activity of drugs/compounds**.

  **No**   **Drug**                                                                                                                           **Strain**                       **Cells**                                **Culture**           **Evaluation**                                                                                                       **Main results**                                                                                                                                               **Effectivity**                                              **Positive control**                        **References**
  -------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ---------------------------------------- --------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------- ------------------------------------
  1        Two novel quinuclidine (ER119884, E5700)                                                                                           RH                               LLCMK2                                   24, 48 h              IC~50~ values[^a^](#TN9){ref-type="table-fn"}                                                                        IC~50~ ER119884, E5700 = 0.66, 0.23 μM                                                                                                                         Effective                                                    Sulfadiazine, pyrimethamine                 Martins-Duarte et al., [@B93]
  2        Fourteen novel ferrocenic atovaquone derivatives                                                                                   76K, PLK, A to R                 HFF                                      48 h                  IC~50~ values                                                                                                        IC~50~ 2d, 2e, 2f = 5.0, 2.5, 6.25 μM                                                                                                                          Effective 2d, 2e, 2f                                         --                                          Baramee et al., [@B14]
  3        Betamethasone and IFN-γ[^b^](#TN10){ref-type="table-fn"}                                                                           RH                               Hela                                     24, 48, 72 h          Counting the number of tachyzoites                                                                                   High number of plaques was seen in group with 40 μg/ml of betamethasone.                                                                                       Betamethasone not effective, IFN--γ effective                --                                          Ghaffarifar et al., [@B59]
  4        Suberoylanilide hydroxamic, suberic bishydroxamic acid, scriptaid, trichostatin A                                                  RH                               HS68 HFF                                 48, 72 h              IC~50~ values                                                                                                        IC~50~ scriptaid = 0.039 μM                                                                                                                                    Scriptaid was the most effective                             --                                          Strobl et al., [@B132]
  5        RWJ67657, RWJ64809[^c^](#TN11){ref-type="table-fn"}, RWJ68198[^d^](#TN12){ref-type="table-fn"}                                     RH, ME49                         HFF                                      48 h                  IC~50~ values                                                                                                        RWJ67657 was at least as potent as RWJ68198, SB203580, or SB202190 in reducing of *T. gondii* replication                                                      RWJ67657, SB203580 effective                                 --                                          Wei et al., [@B145]
  6        Novel drug compounds (A--I) (B,F,G,H) (trifluralin analogs)                                                                        RH                               Vero                                     72 h                  MTT assay[^e^](#TN13){ref-type="table-fn"}, crystal violet assay                                                     IC~50~ drug F = 10 μM                                                                                                                                          Drugs F was the most effective                               --                                          Wiengcharoen et al., [@B147]
  7        1-hydroxy-2-dodecyl-4(1H) quinolone (HDQ)                                                                                          RH                               HFF                                      24 h                  Replication rate determined                                                                                          IC~50~ HDQ = 0.0024 ± 0.0003 μM                                                                                                                                Effective                                                    --                                          Saleh et al., [@B122]
  8        Quinoline derivative MC1626                                                                                                        RH                               HFF                                      24 h                  Standard \[3H\]uracil uptake and plaque assays                                                                       100 μM reducing growth                                                                                                                                         Effective                                                    --                                          Smith et al., [@B130]
  9        N6-benzyladenosine analogs                                                                                                         RH                               HFF                                      24 h                  MTT assay                                                                                                            IC~50~ N6-(2,4-dimethoxybenzyl) Adenosine = 8.7 ± 0.6 μM, exhibited the most favorable activity                                                                Effective                                                    Sulfadiazine, pyrimethamine                 Kim et al., [@B75]
  10       Fluorine-containing aryloxyethyl thiocyanate derivatives                                                                           RH                               HFF                                      24 h                  IC~50~ values                                                                                                        IC~50~ compounds 1 and 3 = 2.80 and 3.99 μM                                                                                                                    Effective                                                    Atovaquone                                  Liñares et al., [@B83]
  11       LHVS, ZL3VS[^f^](#TN14){ref-type="table-fn"}                                                                                       RH or 2F1                        HFF                                      45 min                B gal[^g^](#TN15){ref-type="table-fn"}, Red/green invasion assay, SDS-PAGE, immunoblotting, gliding motility assay   IC~50~ LHVS and ZL3 VS = 10 and 12.5 μM                                                                                                                        Effective                                                    3,4-dichloroisocoumarin                     Teo et al., [@B140]
  12       1,25(OH) 2D3                                                                                                                       RH                               MICc12                                   72 h                  Trypan blue assay                                                                                                    Ruled out any toxic effects of 1,25(OH) 2D 3 for *T. gondii*                                                                                                   Effective                                                    --                                          Rajapakse et al., [@B118]
  13       Tunicamycin                                                                                                                        RH                               HFF                                      2, 24, or 48 h        Fluorescence and electron microscopy                                                                                 N-Glycosylation is completely inhibited by treatment of parasites with tunicamycin                                                                             Effective                                                    Pyrimethamine                               Luk et al., [@B86]
  14       Novel diamidine analogs                                                                                                            RH                               Vero HFF                                 2 or 3 days           IC~50~ values, Q-PCR[^h^](#TN16){ref-type="table-fn"}                                                                IC~50~ DB750, DB786 = 0.16, 0.22 μM                                                                                                                            Effective                                                    --                                          Leepin et al., [@B80]
  15       Pyrimethamine, sulfadiazine, and atovaquone                                                                                        17 strains *T. gondii*           THP-1 MRC-5                              7 days                IC~50~, real-time PCR                                                                                                IC~50~ pyrimethamine = 0.0002, 0.01 μM                                                                                                                         Effective                                                    --                                          Meneceur et al., [@B96]
                                                                                                                                                                                                                                                                                                                                                                   IC~50~ atovaquone = 0.0001, 0.00005 μM                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                   IC~50~ sulfadiazine = 0.01, 0.07 μM for                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                   13 strains and were \> 0.1 μM for three strains                                                                                                                                                                                                                         
  16       Novel triazine JPC-2067-B                                                                                                          RH                               HFF                                      3 days                Liquid scintillation counting                                                                                        IC~50~ JPC-2067-B = 0.02 μM,                                                                                                                                   Effective                                                    --                                          Mui et al., [@B105]
                                                                                                                                                                                                                                                                                                                                                                   IC~90~ JPC-2067-B = 0.05 μM                                                                                                                                                                                                                                             
  17       Newly synthesized bisphosphonates (15 new compounds)                                                                               RH                               Mouse macrophages (J 744A.1)             24, 48 h              MTT assay, flow cytometry                                                                                            91A and 282A showed moderate and low toxicity (cell viability between 70% and 100%)                                                                            Effective                                                    --                                          Shubar et al., [@B128]
  18       2-alkylaminoethyl- 1,1-bisphosphonic acids                                                                                         RH                               HFF                                      Daily                 IC~50~ values, radiometric assay                                                                                     IC~50~ compound 19 = 2.6 μM                                                                                                                                    Compound 19 was very effective                               .                                           Szajnman et al., [@B138]
  19       Itraconazole                                                                                                                       RH                               LLCMK2                                   24 or 48 h            IC~50~ values, TEM[^i^](#TN17){ref-type="table-fn"} analysis                                                         IC~50~ = 0.11, 0.05 μM for 24, 48 h                                                                                                                            Effective                                                    --                                          Martins-Duarte Edos et al., [@B87]
  20       Thiolactomycin analogs (8 new compounds)                                                                                           RH                               LLCMK2                                   24, 48 h              IC~50~ values, Lipid extraction, chromatographic analysis                                                            IC~50~ compounds = 1.6-29.4 μM                                                                                                                                 Compound 5 was very effective                                Sulfadiazine, pyrimethamine                 Martins-Duarte et al., [@B90]
  21       NSC3852[^j^](#TN18){ref-type="table-fn"}                                                                                           RH                               HS 68 HFF                                2 h                   SYBR green assay, MTS assay, ROS assay, NO assays                                                                    EC~50~ NSC3852 = 0.08 μM,                                                                                                                                      NSC3852, NSC74949 were the most effective                    --                                          Strobl et al., [@B133]
                                                                                                                                                                                                                                                                                                                                                                   EC~50~ NSC74949 = 0.6 μM                                                                                                                                                                                                                                                
  22       FR235222, FR235222 derivative compounds (W363, W371, W399, W406, W425)                                                             RH, PRU (type II)                HFF                                      24 h                  EC50 determination, Western blot analysis, immunofluorescence microscopy                                             100% altered cysts 24 h after treatment with the lowest concentration of FR235222                                                                              Effective                                                    --                                          Maubon et al., [@B94]
  23       Thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles                                                                       RH                               Vero                                     24 h                  Mean number of intracellular parasitesa, LD~50~[^k^](#TN19){ref-type="table-fn"}                                     A significant decrease in the percentage of infected cells and in the mean number of tachyzoites per cell from the concentrations of 0.1, 1, 10 mM             Effective                                                    Hydroxyurea, sulfadiazine                   Liesen et al., [@B84]
  24       FLZ[^l^](#TN20){ref-type="table-fn"} and ITZ[^m^](#TN21){ref-type="table-fn"}                                                      RH                               LLCMK2                                   24, 48 h              IC~50~ values                                                                                                        IC~50~ FLZ = 8.9, 3.1 μM after 24, 48 h                                                                                                                        Effective                                                    Sulfadiazine, pyrimethamine                 Martins-Duarte et al., [@B91]
                                                                                                                                                                                                                                                                                                                                                                   IC~50~ ITZ = 0.1, 0.05 μM for 24, 48 h                                                                                                                                                                                                                                  
  25       1-Hydroxy-2-Alkyl-4(1H) Quinolone Derivatives                                                                                      RH (type I)                      HFF                                      24 h                  IC~50~ values                                                                                                        IC~50~ compound A, B = 0.0004, 0.0008 μM                                                                                                                       Effective                                                    Atovaquone                                  Bajohr et al., [@B13]
  26       Oryzalin Analogs                                                                                                                   RH                               HFF                                      8 day 26 h            Plaque assay, Immunofluorescence assay, IC~50~ values                                                                IC~50~ 18b = 0.03 μM                                                                                                                                           Effective                                                    --                                          Endeshaw et al., [@B50]
  27       53 novel compounds (Inhibitors of Enoyl reductase)                                                                                 RH                               HFF                                      3 days                IC~50~ values                                                                                                        IC~50~ compounds 2, 19 = 0.04, 0.02 μM,                                                                                                                        Compounds 2, 19, 39 greatest effect                          --                                          Tipparaju et al., [@B141]
                                                                                                                                                                                                                                                                                                                                                                   IC~50~ compounds 39 less active                                                                                                                                                                                                                                         
  28       Haloperidol, clozapine, fluphenazine, trifluoperazine, thioridazine                                                                RH                               HFF                                      48 h                  IC~50~ values                                                                                                        IC~50~ fluphenazine, thioridazine, trifluoperazine = 1, 1.2, and 3.8 μM                                                                                        Fluphenazine, thioridazine, trifluoperazine were effective   --                                          Goodwin et al., [@B61]
  29       Azithromycin, spiramycin                                                                                                           RH                               Bewo cell line                           24 h                  MTT assay, measurement of Th1/Th2                                                                                    Increase TNF-a[^n^](#TN22){ref-type="table-fn"}, IL-10, IL-4 production, but decreased IFN-γ                                                                   Effective                                                    --                                          Franco et al., [@B56]
  30       Novel azasterols                                                                                                                   RH ME49                          LLCMK2                                   24 or 48 h            IC~50~ values, imunofluorescence assays                                                                              IC~50~ compounds 1, 2, 3 = 0.8--4.7 μM                                                                                                                         Compound 3 was the most effective                            --                                          Martins-Duarte et al., [@B92]
  31       Ciprofloxacin derivatives                                                                                                          RH                               LLC-MK2                                  24 or 48 h            IC~50~, MTS assay                                                                                                    IC~50~ compounds 2, 4, 5= 0.42, 1.24, and 0.46 μM                                                                                                              Effective                                                    --                                          Dubar et al., [@B43]
  32       2-hydrazolyl-3-phenyl-5-(4-nitrobenzylidene)-4-thiazolidinone substituted                                                          RH                               Vero                                     24 h                  LD~50~ values                                                                                                        LD~50~ = 0.5, 10 mM                                                                                                                                            Effective                                                    Hydroxyurea, Sulfadiazine                   Aquino et al., [@B8]
  33       Nanoparticles                                                                                                                      RH (CAT-GFP)                     Macrophages J 774-A1                     3 day                 HPLC[^o^](#TN23){ref-type="table-fn"}: flow cytometry                                                                Ca[^p^](#TN24){ref-type="table-fn"}.85% observed maximum in Toxoplasmosis therapy efficiency                                                                   Effective                                                    --                                          Leyke et al., [@B81]
  34       Enrofloxacin                                                                                                                       RH                               HFF                                      72 h                  MTT assays                                                                                                           Enrofloxacin resulted in a significant inhibition of the percentage of infected cells by the parasite (58.72%)                                                 Effective                                                    Sulfadiazine, pyrimethamine                 Barbosa et al., [@B15]
  35       ELQ-271 and ELQ-316[^q^](#TN25){ref-type="table-fn"}                                                                               2F                               HFF                                      4 days                Host-cell toxicity                                                                                                   IC~50~ ELQ-271, ELQ-316 = 0.0001, and 0.000007 μM                                                                                                              Effective                                                    Atovaquone                                  Doggett et al., [@B41]
  36       Pterocarpanquinone                                                                                                                 RH                               LLCMK2                                   24 or 48 h            Direct counts, viability, imunofluorescence assays                                                                   IC~50~= 2.5 μM                                                                                                                                                 Effective                                                    --                                          Portes Jde et al., [@B116]
  37       New naphthoquinones and an alkaloid                                                                                                RH, EGS                          HFF                                      48 h                  MTT assays                                                                                                           IC~50~ QUI-5, and QUI-6[^r^](#TN26){ref-type="table-fn"} = 69.35, and 172.81 μM                                                                                Effective                                                    Atovaquone, Sulfadiazine                    Ferreira et al., [@B51]
  38       Spiramycin coadministered with metronidazole                                                                                       ME49                             Vero E6                                  1 week                Numbers of cysts and tachyzoites                                                                                     Spiramycin reduced *in vitro* reactivation, metronidazole alone did not have significant effect                                                                Effective                                                    --                                          Chew et al., [@B28]
  39       Di-cationic pentamidine-analogs                                                                                                    RH ME49                          HFF                                      72 h                  Cytotoxicity assays                                                                                                  IC~50~ arylimidamide DB745 = 0.11, 0.13 μM (tachyzoites of Rh, Me49)                                                                                           Effective                                                    Atovaquone                                  Kropf et al., [@B77]
  40       Small-Molecule (*n*=527)                                                                                                           Strains 5A10 (type III strain)   HFF                                      72 h                  Luciferasebased assay, Host cell viability, electron microscopy, invasion, motility assays                           EC~50~ s for the 14 compounds = 0.14--8.7 μM                                                                                                                   14 compounds effect                                          --                                          Kamau et al., [@B72]
  41       Salicylic acids (39 compounds)                                                                                                     RH, RH-YFP, and ME49             HFF                                      1 h                   \[3H\]-Uracil incorporation and YFP Fluorescence assay                                                               3i, 3j, 7a, 14a, and 14b were active at low nanomolar concentrations                                                                                           Effective                                                    Pyrimethamine, Sulfadiazine                 Fomovska et al., [@B54]
  42       FLZ combined with sulfadiazine and pyrimethamine                                                                                   RH                               LLCMK2                                   24 h                  IC50 values and MTS assay                                                                                            IC~50~ FLZ = 8.4 ± 1.2, IC~50~ sulfadiazine/pyrimethamine, pyrimethamine = 8.7 ± 0.8 μM                                                                        Effective                                                    --                                          Martins-Duarte et al., [@B88]
  43       Harmane, Norharmane (β-carboline alkaloids)                                                                                        RH                               Vero HFF                                 1, 24 h               Parasite invasion and replication rate                                                                               harmane and harmine showed 2.5- to 3.5-fold decrease in the invasion rates at doses of 40 μM, norharmane 2.5 μM                                                Effective                                                    Sulfadiazine                                Alomar et al., [@B5]
  44       Fusidic acid                                                                                                                       Prugniaud                        HFF                                      7 days                Lytic plaques counted                                                                                                IC~50~ = 7.7 μM, decreased the number of *T. gondii* plaques in a dosedependent manner                                                                         Effective                                                    --                                          Payne et al., [@B113]
  45       Two naphthalene-sulfonyl-indole compounds                                                                                          RH                               --                                       1.5 h                 Stained by PI, analyzed by FACS                                                                                      LD~50~ compound A, B = 62, 800 μmol                                                                                                                            Effective                                                    Saponin                                     Asgari et al., [@B10]
  46       (Benzaldehyde)-4-phenyl-3- thiosemicarbazone, (benzaldehyde)-(4 or 1)- phenylsemicarbazone (9 compounds)                           RH                               Vero                                     24 h                  Cytotoxicity, number of intracellular parasites                                                                      LD~50~ compound 8 = 0.3 mM, reduced the number of intracellular parasites by 82 % in a concentration of 0.01 mM                                                Effective                                                    Sulfadizine                                 Gomes et al., [@B60]
  47       Ivermectin and sulphadiazine                                                                                                       RH                               Hep- 2                                   24, 48, 72 h          IC~50~, invert microscopy, ELISA assay                                                                               IC~50~ ivermectin and sulphadiazine = 0.2, and 29.1 μM                                                                                                         Effective                                                    --                                          Bilgin et al., [@B19]
  48       Novel ruthenium complexes                                                                                                          RH                               HFF                                      72 h                  cytotoxicity assessment, TEM                                                                                         EC~50~ compounds 16, 18 = 18.7, 41.1 nM                                                                                                                        Compounds 16, and 18 effective                               --                                          Barna et al., [@B16]
  49       Atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir, and saquinavir                                                        RH                               Macrophages Swiss Webster                48 h                  IC~50~ determination, MTT assay                                                                                      IC~50~ atazanavir ritonavir, and saquinavir = \> 1 μM                                                                                                          Effective                                                    Pyrimethamine                               Monzote et al., [@B104]
                                                                                                                                                                                                                                                                                                                                                                   IC~50~ fosamprenavir, and nelfinavir = \> 5 μM                                                                                                                                                                                                                          
  50       Atorvastatin                                                                                                                       RH                               HFF                                      8 days                IC~50~ values                                                                                                        IC~50~ = 50 μM                                                                                                                                                 Effective                                                    --                                          Li et al., [@B82]
  51       Nitaxozanide                                                                                                                       RH                               Astrocyte                                24,48 h               Immunocytochemical method, microscopic analysis, viability                                                           Nitazoxanide produced 97% *T. gondii* death in a concentration of 10 mg/mL in 48 h infected astrocytes                                                         Effective                                                    Pyrimethamine                               Galván-Ramírez et al., [@B58]
  52       Amisulpride, cyamemazine, fluphenazine, haloperidol, levomepromazine, loxapine, olanzapine, risperidone, tiapride, and valproate   RH                               HFF                                      4 h                   Growth inhibition assay                                                                                              Amisulpride, tiapride and valproate did not have inhibitory activity                                                                                           Zuclopenthixol, high effective                               --                                          Fond et al., [@B55]
  53       Spiroindolone                                                                                                                      RH                               HFF                                      72 h                  Fluorescence assays, cytotoxicity assessment                                                                         IC~50~ = 1 μM                                                                                                                                                  Effective                                                    Pyrimethamine, sulfadiazine                 Zhou et al., [@B155]
  54       Auranofin                                                                                                                          RH                               HFF                                      5 days                Invasion and replication assays and plaque assays                                                                    TD~50~ = 8.21 μM, IC~50~ = 0.28 μM                                                                                                                             Effective                                                    Pyrimethamine, Sulfadiazine                 Andrade et al., [@B6]
  55       Azithromycin                                                                                                                       2 F1                             Placental tissues                        48 h                  Production of cytokines and hormones                                                                                 Increases IL-6 production, reduced secretion of estradiol, progesterone, and HCG + β                                                                           Effective                                                    Pyrimethamine, Sulfadiazine, folinic acid   Castro-Filice et al., [@B25]
  56       6-Trifluoromethyl-2-thiouracil (ATT-5126), (KH-0562)                                                                               RH                               Hela                                     24 h                  MTS assay, IC~50~                                                                                                    IC~50~ ATT-5126, KH-0562 = 19.7, 32.2 μM                                                                                                                       Effective                                                    Pyrimethamine                               Choi et al., [@B30]
                                                                                                                                                                                                                                                                                                                                                                   CC~50~ ATT-5126, KH-0562 = 35.4, 56.3 μM                                                                                                                                                                                                                                
  57       Cromolyn sodium and ketotifen                                                                                                      RH                               Macrophage monolayer                     24 h                  Inhibition rate                                                                                                      After 60 min the best efficacy was observed at 15 μg/ml (78.9 ± 1.70, 91.97 ± 0.37%)                                                                           Effective                                                    --                                          Rezaei et al., [@B119]
  58       200 drug-like and 200 probe-like compounds of Malaria Box                                                                          TS-4 (mutant of the RH)          HFF                                      24 h                  Cytotoxicity assays                                                                                                  Seven compounds with IC~50~ \< 5 μM, SI \> 6                                                                                                                   7 compounds effected                                         Pyrimethamine, sulfadiazine                 Boyom et al., [@B23]
  59       Am80                                                                                                                               RH, PLK, its recombinants        J 774A.1                                 20 h                  Uracil incorporation assay, RT--PCR[^s^](#TN27){ref-type="table-fn"}, flow cytometry                                 Am80 inhibited parasite growth by decreasing intracellular accumulation of cholesterol                                                                         Effective                                                    --                                          Ihara and Nishikawa, [@B66]
  60       Pyrimethamine --loaded lipid-core nanocapsules                                                                                     RH                               LLC-MK2                                  72 h                  MTS assay                                                                                                            TC~50~ PYR loaded lipid-core nanocapsules = 6.0 μM                                                                                                             Effective                                                    --                                          Pissinate et al., [@B115]
  61       Quinoline derivatives (58 compounds)                                                                                               2F                               HFF                                      4 days                Cytotoxicity assays                                                                                                  IC~50~ B23 = 0.4 ± 0.03 μM, the most effective compound                                                                                                        32 compounds effected                                        --                                          Kadri et al., [@B71]
  62       74 novel thiazolidin-4-one derivatives                                                                                             --                               HFF                                      5 days                Cytotoxicity assays                                                                                                  IC~50~ derivatives 12 A, 27 A = 0.9, 2.9 μM                                                                                                                    Effective                                                    Timethoprim                                 D\'Ascenzio et al., [@B35]
  63       Gefitinib and Crizotinib                                                                                                           RH                               Hela                                     24, 48, 72 h          Counting the number of *T. gondii* per parasitophorous vacuolar membrane                                             Gefitinib inhibited the growth of *T. gondii* over 5 μM whereas Sunitinib did not                                                                              Gefitinib effected                                           Pyrimethamine                               Yang et al., [@B149]
  64       1,4-disubstituted thiosemicarbazides                                                                                               RH                               Mouse L929 fibroblasts                   24 h                  MTT assay and q-pcr                                                                                                  1g, 2b, 3d, 3l showed significant anti-parasitic effects                                                                                                       1 g was very effective                                       Sulfadiazine                                Dzitko et al., [@B45]
  65       3-(thiophen-2-yl)-1,2,4-triazole-5-thione                                                                                          RH                               Mouse L929 fibroblasts                   24 h                  IC~50~ values and q-pcr                                                                                              IC~50~ at least 30 times better than that of sulfadiazine                                                                                                      Effective                                                    Sulfadiazine                                Dzitko et al., [@B46]
  66       1-\[4-(4-nitrophenoxy) phenyl\]propane-1-one (NPPP)                                                                                RH                               Hela                                     24 h                  CC~50~, EC~50~ values                                                                                                EC~50~, CC~50~ = 36.2 ± 0.2, 67.0 ± 0.2 μM                                                                                                                     Effective                                                    --                                          Choi et al., [@B29]
  67       C-type lectin from Bothropspauloensis venom                                                                                        RH                               Hela                                     24 h                  MTT assay, cytokine measurements                                                                                     MTT assay between 0.195, 12.5 μg/mL MIF, IL-6 productions were increased                                                                                       Effective                                                    --                                          Castanheira et al., [@B24]
  68       Ciprofloxacin derivatives Compounds (2, 4, 5)                                                                                      RH                               LLCMK2 HFF                               24, 48, 72 h          Immunofluorescence, TEM                                                                                              Inhibited parasite replication early in the first cycle of infection                                                                                           Effective                                                    --                                          Martins-Duarte et al., [@B89]
                                                                                                                                                                                                                        6 h                                                                                                                                                                                                                                                                                                                                                                                                                
  69       New chiral N-cylsulfonamide bis-oxazolidin-2-ones                                                                                  RH                               MRC-5                                    --                    IC~50~ values                                                                                                        IC~50~ of Mol 1 was less than Mol 2                                                                                                                            Effective                                                    Sulfadiazine                                Meriem et al., [@B97]
  70       Guanabenz                                                                                                                          ME49 Prugniaud                   HFF                                      32 h                  EC~50~ values                                                                                                        EC~50~ = 6 μM                                                                                                                                                  Effective                                                    --                                          Benmerzouga et al., [@B17]
  71       3-Bromopyruvate, Atovaquone                                                                                                        RH                               LLC-MK2                                  24, 48 h, or 6 days   Light-microscopic analysis, indirect immunofluorescent assays                                                        73 and 71% reduction in intracellular parasites after 24, 48 h                                                                                                 Effective                                                    --                                          de Lima et al., [@B36]
  72       Biphenylimidazoazines                                                                                                              RH                               HFF                                      96 h                  EC~50~ values and fluorescence microscopy assay                                                                      EC~50~ \< 1 μM                                                                                                                                                 Effective                                                    Pyrimethamine                               Moine et al., [@B99]
  73       Halofuginone                                                                                                                       RH                               HFF                                      24 h                  EC~50~ values                                                                                                        EC~50~ = 0.94 nM                                                                                                                                               Effective                                                    Pyrimethamine                               Jain et al., [@B68]
  74       Naphthoquinone derivative                                                                                                          RH                               LLC-MK2                                  24, 48 h              IC~50~ and MTT assay                                                                                                 IC~50~ LQB 151 = \< 1 μM                                                                                                                                       Effective                                                    --                                          da Silva et al., [@B34]
  75       Aryloxyethyl thiocyanates                                                                                                          RH                               Vero                                     24 h                  Determination of ED~50~                                                                                              ED~50~ derivatives 15 and 16 = 1.6 μM and 1.9 μM                                                                                                               Effective                                                    --                                          Chao et al., [@B27]
  76       Imidazo \[1,2-b\] pyridazines derivatives                                                                                          RH-GFP                           HFF                                      24 h                  Cytotoxicity assay                                                                                                   EC~50~ 16a, 16f = 100, 70 nM                                                                                                                                   Effective                                                    --                                          Moine et al., [@B100]
  77       Nitrofurantoin                                                                                                                     RH                               Hela                                     24 h                  MTS assay                                                                                                            Selectivity = 2.3                                                                                                                                              Effective                                                    Pyrimethamine                               Yeo et al., [@B150]
                                                                                                                                                                                                                                                                                                                                                                   EC~50~ = 14.7 μM                                                                                                                                                                                                                                                        
  78       Quinoxalinone derivatives                                                                                                          RH                               HEp-2[^t^](#TN28){ref-type="table-fn"}   24 h                  IC~50~ values, viability, invasion, and intracellular growth                                                         MIC~50~ VAM2-2 = 3.3 ± 1.8 μM                                                                                                                                  VAM2-2 was very effective                                    --                                          Fernández et al., [@B120]
  79       1120 compounds                                                                                                                     RH-GFP                           HFF                                      72 h                  Parasite invasion, Microneme secretion, Luciferase, and LC3-GFP assays                                               94 compounds with IC50 \< 5 μM                                                                                                                                 Tamoxifen effective                                          --                                          Dittmar et al., [@B40]
  80       3-aminomethyl benzoxaborole (AN6426)                                                                                               RH                               HFF                                      24 h                  Determination of EC~50~                                                                                              EC~50~ = 76.9 μM                                                                                                                                               Effective                                                    Pyrimethamine                               Palencia et al., [@B111]
  81       Sulfur-containing linear bisphosphonates                                                                                           RH, Prugniard                    Human fibroblasts (hTert cells)          5 days                Determination of EC~50~                                                                                              EC~50~ = 0.11 ± 0.02 μM                                                                                                                                        Compound 22 was very effective                               --                                          Szajnman et al., [@B137]
  82       Fluorine-containing Analogs of WC-9 (4-phenoxyphenoxyethyl thiocyanate)                                                            RH                               Vero                                     24 h                  Determination of EC~50~                                                                                              EC~50~ 3-(3-fluorophenoxy), 3-(4-fluorophenoxy) phenoxyethyl thiocyanates, and 2-\[3-(phenoxy)phenoxyethylthio\]ethyl-1,1-bisphosphonat = 1.6 4.9 and 0.7 μM   Effective                                                    --                                          Chao et al., [@B26]
  83       6-(1,2,6,7-tetraoxaspiro\[7.11\] nonadec-4-yl)hexan-1-ol (N-251)                                                                   RH                               Human hepatocyte, Huh-7                  72 h                  IC~50~ values, q-pcr, ultrastructural Change by TEM                                                                  LC~50~ = 1.11 μg/ml                                                                                                                                            Effective                                                    Sulfadiazine                                Xin et al., [@B148]

*Half maximal inhibitory concentration*.

*Interferon gamma*.

*Pyridinylimidazole*.

*Imidazopyrimidine*.

*3− (4, 5−Dimethyl−2−Thiazyl) − 2, 5−Diphenyl−2H−Tetrazoliu Bromide*.

*Morpholinourea-leucyl-homophenolalaninyl-phenyl-vinylsulfone, N-benzoxycarbonyl-(leucyl) 3-phenyl-vinyl-sulfone*.

*B galactosidase*.

*Quantitative polymerase chain reaction*.

*Transmission electron microscopy*.

*5- nitroso-8-quinolinol*.

*Lethal Dose, 50%*.

*Fluconazole*.

*Itraconazole*.

*Tumor necrosis factor*.

*High Performance Liquid Chromatography*.

*Carriers achieved*.

*Endochin-like quinolones*.

*7-(4-methyl-3-pentenyl)-2-pyrrolidine-\[1, 4\]-naphthoquinone (QUI-5), 6-(4-methyl-3-pentenyl)-2-pyrrolidine-\[1, 4\]-naphthoquinone (QUI-6)*.

*Reverse transcription polymerase chain reaction*.

*Human larynx epidermoid carcinoma epithelial cells*.

###### 

**Summary of ***in vivo*** studies evaluated the anti-***Toxoplasma*** activity of drugs/ compounds**.

  **No**   **Drug**                                                                                                                **Animal**                     **Strain**              **Type of infection**     **Inoculum**                                                               **Treatment**                                                                                                                  **Assessment of efficacy**                                                                                                                                                                                                  **Main results**                                                                                                                                          **Effectivity**                                         **Positive control**             **References**
  -------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------ ----------------------- ------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- -------------------------------- ----------------------------------
  1        PHNQ6[^a^](#TN29){ref-type="table-fn"} alone or combined with sulfadiazine                                              Female Swiss mice              RH EGS P                Acute, chronic            1000 tachyzoites (ip) 10 brain cysts (orally)                              PHNQ6 50 mg/kg/day Sulfadiazine, 40 mg/L                                                                                       Survival rates, IFAT[^b^](#TN30){ref-type="table-fn"}, and liver histology                                                                                                                                                  Treatment protected at least 70, 90% of mice infected with RH and EGS strains                                                                             Effective                                               Sulfadiazine                     Ferreira et al., [@B52]
  2        1, 25(OH) 2D3                                                                                                           BALB/c                         ME49                    Acute                     20 cysts                                                                   0.5 μg/kg/2 days ip                                                                                                            Histopathology, RT-PCR[^c^](#TN31){ref-type="table-fn"}                                                                                                                                                                     Low parasitic burdens were found                                                                                                                          Effective                                               --                               Rajapakse et al., [@B118]
  3        Pyridinylimidazole (RWJ67657, RWJ64809), imidazopyrimidine (RWJ68198)                                                   Female CBA/J, CD8 / --         RH ME49                 Acute                     1000, 100, and 20 tachyzoites                                              3.8, 7.5, 15, 30, or 60 mg/kg i.p                                                                                              Survival rates                                                                                                                                                                                                              The highest dose (60 mg/kg) significantly improved survival                                                                                               RWJ67657 effective                                      --                               Wei et al., [@B145]
  4        Novel triazine JPC-2067-B                                                                                               Outbred Swiss Webster          RH                      Acute                     10000 tachyzoites i.p                                                      1.25 mg/kg/day orally                                                                                                          Peritoneal *T. gondii* burden                                                                                                                                                                                               Intraperitoneal parasite numbers were reduced                                                                                                             Effective                                               --                               Mui et al., [@B105]
  5        Newly synthesized bisphosphonates                                                                                       NMRI                           RH                      Acute                     100 000 tachyzoites i.p                                                    490, 1000, 512, 44.05, and 47.6 μM                                                                                             Flow cytometry                                                                                                                                                                                                              Therapeutic efficacy was 100% for bisphosphonates 2F, 3B, 18A, 22A, and 30B                                                                               Effective                                               --                               Shubar et al., [@B128]
  6        Azithromycin, Artemisia annua, spiramycin, SPFA                                                                         Females C. callosus            ME49                    Chronic                   20 cysts                                                                   Azithromycin (9 mg/24 h), A. annua (1.0 mg/8 h), spiramycin (0.15 mg/8 h)                                                      Morphological, immunohistochemical analyses, mouse bioassay, and PCR[^d^](#TN32){ref-type="table-fn"}                                                                                                                       No morphological changes were seen in the placenta and embryonic tissues from females treated with azithromycin, spiramycin, and SPFA                     Azithromycin more effective                             --                               Costa et al., [@B32]
  7        Dihydroartemisinin and azithromycin                                                                                     Kunming mice                   .                       Acute                     2 × 10^3^tachyzoites                                                       Dihydroartemisinin and azithromycin 75 and 200 mg/kg                                                                           The ultrastructure of tachyzoites                                                                                                                                                                                           The ultrastructure of tachyzoites was observed in the treatment groups such as edema, enlarged, broken or damaged                                         Effective                                               --                               Yin et al., [@B151]
  8        FLZ[^f^](#TN34){ref-type="table-fn"} and ITZ[^g^](#TN35){ref-type="table-fn"}                                           Outbred female Swiss           CF1 ME49                Chronic                   20 cysts of the ME~49~ orally or i.p                                       10,20 mg/kg/day orally                                                                                                         Survival rates and brain cyst burden                                                                                                                                                                                        ITZ survival of 90, 87% FLZ survival rate of 71, 85%                                                                                                      Effective                                               Sulfadiazine, pyrimethamine      Martins-Duarte et al., [@B91]
  9        HDQ[^h^](#TN36){ref-type="table-fn"} derivatives                                                                        Female NMRI, IRF-8 /--         RH ME49                 Acute, chronic            10^5^ green fluorescent protein, i.p 10 cysts                              32 mg/kg body weight/day                                                                                                       Parasite loads in lungs, livers by qPCR[^e^](#TN33){ref-type="table-fn"}, and flow cytometry analyses                                                                                                                       Derivatives of HDQ had lower parasite concentrations than mice treated with HDQ                                                                           Effective                                               Atovaquone                       Bajohr et al., [@B13]
  10       FR235222, FR235222 derivative, (W363, W371, W399, W406, W425)                                                           Outbred female Swiss           PRU                     Chronic                   Living cysts i.p                                                           200 nM                                                                                                                         Presence or absence of cysts in brain was assessed by staining                                                                                                                                                              No cysts were detected in mice inoculated with FR235222-treated                                                                                           Effective                                               Pyrimethamine                    Maubon et al., [@B94]
  11       Azithromycin combined with metronidazole                                                                                BALB/c                         --                      Acutly                    50 tissue cysts orally or i.p                                              250, 200 mg/kg/day                                                                                                             Microscopical examination, bioassay were done for brain, and survival rates                                                                                                                                                 Cure rate 100%                                                                                                                                            Effective                                               --                               H.Al-jader and Al-Mukhtar, [@B1]
  12       Novel compounds 2,19 (Inhibitors of Enoyl Reductase)                                                                    CD1                            RH                      Acute                     2000                                                                       10 mg/kg i.p                                                                                                                   Parasite burdens in the peritoneal cavity and survival rates                                                                                                                                                                Reduction of parasite burden                                                                                                                              Effective                                               --                               Tipparaju et al., [@B141]
  13       SDS-coated atovaquone                                                                                                   C57BL/6                        ME49                    Acute, chronic            10 cysts orally                                                            100 mg/kg                                                                                                                      Histology, PCR                                                                                                                                                                                                              Parasite loads and inflammatory changes in brains were significantly reduced                                                                              Effective                                               --                               Shubar et al., [@B127]
  14       1NM-PP1                                                                                                                 Old female ICR strain          RH                      Acute                     1.0 × 10^5^ tachyzoites i.p                                                5 μM orally                                                                                                                    Survival rates, parasite load by qPCR                                                                                                                                                                                       Reduced the parasite load in the brains, livers, lungs                                                                                                    Effective                                               --                               Sugi et al., [@B134]
  15       Enrofloxacin                                                                                                            Calomys callosus, C57BL/6      RH ME49                 Acute, chronic            100 tachyzoites RH strain 20 cysts per 100/ l (orally)                     Subcutaneously for 3 days, 3 mg/kg twice a week for the duration of 25-day                                                     Histological analysis, immunohistochemical assay, survival, cyst counts                                                                                                                                                     diminished significantly the tissue parasitism as well as the inflammatory alterations in the brain                                                       Effective                                               Sulfadiazine, pyrimethamine      Barbosa et al., [@B15]
  16       Small-Molecule (C1, C2, C3, C5)                                                                                         BALB/c                         5A10, PB3-10            Acute, chronic            10,000 tachyzoites i.p                                                     4.4 mg/kg/day                                                                                                                  Survival rates, recording the total number of photons per second from each mouse                                                                                                                                            C2 showed a significant reduction in parasite load in acute and reduced levels of parasite proliferation and increased survival in chronic phase          C2 effective                                            --                               Kamau et al., [@B72]
  17       Endochin-like quinolones (ELQ-271, ELQ-316)                                                                             Female CF-1 CBA/J              RH ME49                 Acute, chronic            20000 tachyzoites (express YFP) i.p 18 cysts of ME49                       50, 20, 5, 1 mg/kg for 5 day                                                                                                   Counted by flow cytometry                                                                                                                                                                                                   ED50 values of 0.14, 0.08 mg/kg reducing cyst burden by 76--88%                                                                                           Effective                                               Atovaquone                       Doggett et al., [@B41]
                                                                                                                                                                                                                                                                                               5 or 25 mg/kg for 16 day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  18       Spiramycin coadministered with metronidazole                                                                            Male BALB/c                    ME49                    Chronic                   1000 tachyzoites orally                                                    400 mg/kg daily for 7 days                                                                                                     Brain cysts counted                                                                                                                                                                                                         Metronidazole increased spiramycin brain penetration, causing a significant reduction of *T. gondii* brain cysts                                          Metronidazole alone showed no effect                    --                               Chew et al., [@B28]
                                                                                                                                                                                                                                                                                               500 mg/kg daily                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  19       New naphthoquinones, an alkaloid                                                                                        Female Swiss-Webster           EGS                     Chronic                   10 tissue cysts orally                                                     50 μg/mL of QUI-11, 100 μg/mL of either QUI-6 or QUI-11                                                                        Presence of tachyzoites in the peritoneal cavities and survival rates                                                                                                                                                       The survival rates increased                                                                                                                              Effective                                               Atovaquone                       Ferreira et al., [@B51]
  20       Prednisolone                                                                                                            Swiss albino                   RH ME49                 Acute, chronic            1 × 10^4^ tachyzoites, iP                                                  235, 470, 705 mg/kg                                                                                                            Number of tachyzoites present                                                                                                                                                                                               Greatly improved the number of tachyzoite, cyst forms in mice                                                                                             No effective                                            --                               Puvanesuaran et al., [@B117]
  21       Salicylic acids compounds 14a, 14b                                                                                      Swiss Webster                  RH, RH-YFP, ME49        Acute                     Oocysts orall gavage                                                       100 or 25 mg/kg orally                                                                                                         Survival rates                                                                                                                                                                                                              Increased survival by 1 day                                                                                                                               Effective                                               Pyrimethamine, sulfadiazine      Fomovska et al., [@B54]
  22       Atorvastatin                                                                                                            Female Swiss Webster, BALB/c   RH TATi                 Acute                     5--20 tachyzoites i.p 10,000--100,000 tachyzoites                          20 mg/kg/day ip                                                                                                                Plaque assays and containing tachyzoites in peritoneal fluid                                                                                                                                                                Atorvastatin protect mice against death, cures a lethal infection                                                                                         Effective                                               --                               Li et al., [@B82]
  23       Fusidic acid                                                                                                            Female BALB/c                  Prugniaud               Acute                     5 × 10^3^ or 5 × 10^4^ tachyzoites i.p                                     20 mg/kg                                                                                                                       Parasite burdens, analyses of host cytokine, and survival rates                                                                                                                                                             There was no statistically significant difference between mice treated with fusidic acid versus saline                                                    No effective                                            Trimethoprim, sulfadiazine       Payne et al., [@B113]
  24       FLZ combined with sulfadiazine, and pyrimethamine                                                                       CF1                            RH                      Acute                     10^3^ tachyzoites                                                          10 mg/kg/day of fluconazole with 40/1 mg/kg/day sulfadiazine, pyrimethamine                                                    Survival rates                                                                                                                                                                                                              93% survival                                                                                                                                              Effective                                               Sulfadiazine, pyrimethamine      Martins-Duarte et al., [@B88]
  25       Two naphthalene-sulfonyl-indole compounds                                                                               BALB/c                         RH                      Acute                     2 × 10^6^ tachyzoites                                                      25--800 μmol i.p                                                                                                               Survival rates, liver touch smears with giemsa stained                                                                                                                                                                      Both of the compounds was preserved                                                                                                                       Effective                                                                                Asgari et al., [@B10]
  26       Toltrazuril                                                                                                             lambs                          ME49                    Chronic                   1 × 10^5^oocysts                                                           20, 40 mg/kg orally 2 times, once every week                                                                                   Presence of tissue cysts by histopathology, immunohistochemistry, and nested-PCR                                                                                                                                            Cyst presence was determined as 44.4%                                                                                                                     Effective                                                                                Kul et al., [@B78]
  27       Auranofin                                                                                                               Chicken embryos                RH                      Acute                     1 × 10^4^ tachyzoites chorioallantoic vein                                 1 mg/kg                                                                                                                        Histopathology, immunohistochemistry, and qPCR                                                                                                                                                                              Significantly reduced parasite load                                                                                                                       Effective                                               Pyrimethamine, sulfadiazine      Andrade et al., [@B6]
  28       Spiroindolone                                                                                                           Mice                           RH                      Acute                     2000 tachyzoites                                                           100 mg/kg/day                                                                                                                  Parasite burdens, measuring the fluorescence intensity                                                                                                                                                                      Reduced the parasite burden in mice by 90%                                                                                                                Effective                                               --                               Zhou et al., [@B155]
  29       6-Trifluoromethyl-2-thiouracil KH-0562[^i^](#TN37){ref-type="table-fn"} and ATT-5126[^j^](#TN38){ref-type="table-fn"}   ICR female                     RH                      Acute                     1 × 10^5^ tachyzoites                                                      100 mg/kg KH-0562[^i^](#TN37){ref-type="table-fn"} or ATT-5126[^j^](#TN38){ref-type="table-fn"} orally                         Measuring amount of the tachyzoites in mice ascites,LPO[^k^](#TN39){ref-type="table-fn"}, GSH[^l^](#TN40){ref-type="table-fn"}, ALT[^m^](#TN41){ref-type="table-fn"}, AST[^n^](#TN42){ref-type="table-fn"} in mouse liver   LPO level-KH-0562 and ATT-5126 = 87.4 and 105.2 nmol/g                                                                                                    KH-0562 more effective                                  Pyrimethamine                    Choi et al., [@B30]
  30       Pyrazolopyrimidine-1294                                                                                                 BALB/c                         RH Pru                  Acute, chronic            10^5^ tachyzoites                                                          100, 30 mg/kg/day for 5 days                                                                                                   Survival rates and number of *T. gondii* per ml                                                                                                                                                                             Decreasing the numbers of *T. gondii* tachyzoites at both 100, 30 mg/kg                                                                                   Effective                                               --                               Doggett et al., [@B42]
  31       6-Trifluoromethyl-2-thiouracil KH-0562[^i^](#TN37){ref-type="table-fn"}, ATT-5126[^j^](#TN38){ref-type="table-fn"}      Female ICR                     RH                      Acute                     1 × 10^5^ tachyzoites                                                      100 mg/kg                                                                                                                      Proteomic profiles of *T. gondii* tachyzoites                                                                                                                                                                               Decreased the amount of tachyzoites, mean numbers of tachyzoites = (66.8 ± 0.8) × 10^6^                                                                   Effective                                               Pyrimethamine                    Choi et al., [@B30]
  32       Cromolyn sodium, ketotifen                                                                                              Balb/c                         RH                      Acute                     4 × 10^5^ tachyzoites                                                      Ketotifen 1, 2 mg/kg, cromolyn sodium 5, 10 mg/kg, ip                                                                          Inhibition evaluated under a light microscope with giemsa staining                                                                                                                                                          After 60 min ketotifen at 2 mg/kg (69.83 ± 2.25 %), cromolyn sodium, at 10 mg/kg in (80.47 ± 2/49 %) had the best effect                                  Effective                                               --                               Rezaei et al., [@B119]
  33       Diclazuril plus atovaquone                                                                                              CD1 mice                       PTG Strain              Chronic                   600 tachyzoites-i.p                                                        65, 120 mg/kg diclazuril                                                                                                       Hematoxylin eosin,Giemsa,immuno histochemical staining                                                                                                                                                                      Combination diclazuril plus atovaquone was safe                                                                                                           Effective                                               --                               Oz, [@B110]
  34       Diclazuril plus atovaquone                                                                                              CD1 mice                       PTG strain              Chronic                   300, or 600 tachyzoites i.p                                                65, 120 mg/kg diclazuril                                                                                                       Hematoxylin and eosin, slides evaluated of colonic tissues                                                                                                                                                                  Combined therapy synergistically normalized pathology and to a lesser degree monotherapy                                                                  Effective                                               --                               Oz, [@B109]
  35       Am80                                                                                                                    BALB/c mice                    RH, PLK                 Acute                     1 × 10 ^3^ tachyzoites i.p                                                 1 mg/kg                                                                                                                        Survival rates                                                                                                                                                                                                              Percent survival of mice increased statistically                                                                                                          Effective                                               --                               Ihara and Nishikawa, [@B66]
  36       Chitosan and silver nanoparticles                                                                                       Swiss albino                   RH                      Acute                     3.5 × 10^3^ tachyzoites i.P                                                100, 200 μg/ml                                                                                                                 Parasite density and ultrastructural parasite changes                                                                                                                                                                       Statistically significant decrease in the mean number of the parasite count in the liver and the spleen                                                   Effective                                               Pyrimethamine                    Gaafar et al., [@B57]
  37       Pyrimethamine/sulfadiazine                                                                                              Female C57BL/6 mice            ME49                    Chronic                   20 cysts i.p                                                               Pyrimethamine, sulfadiazine 4, 100 mg/kg daily for one month                                                                   Histology, qPCR, measured KP metabolites                                                                                                                                                                                    Significant increases in these kynurenine pathway metabolites were observed in the brain at 28 days post-infection                                        Effective                                               --                               Notarangelo et al., [@B107]
  38       Pyrimethamine-loaded lipid-core nanocapsules                                                                            Female CF1 mice                RH                      Acute                     10^3^ tachyzoites                                                          5.0--10 mg/kg/day                                                                                                              Surviving mice, cyst brain evaluation, bioassay urea, AST and ALP[^o^](#TN43){ref-type="table-fn"}                                                                                                                          Survival rate higher than the animals treated with the same doses of non-encapsulated pyrimethamine                                                       Effective                                               --                               Pissinate et al., [@B115]
  39       Atovaquone and astragalus combination                                                                                   BALB/c                         RH                      Acute                     2 × 10^4^/ml trophozoites                                                  Atovaquone, astragalus 100, 0.075 mg/kg/day oral gavage                                                                        Peritoneal trophozoite numbers, IL-2, IL-12, IFN-γ[^p^](#TN44){ref-type="table-fn"} levels were determined by ELISA                                                                                                         The number of trophozoites in the combination groups were found significantly lower than the number of trophozoites in the control group                  Effective                                               --                               Sönmez et al., [@B131]
  40       Rolipram                                                                                                                Female Swiss albino mice       KSU strain              Chronic                   20 tissue cysts                                                            10 mg/kg daily for three weeks                                                                                                 Life expectancy, serum Alt, histopathology of liver and brain                                                                                                                                                               Rolipram exerts a significant lowering effect on ALT levels, pathology                                                                                    Partially effective                                     --                               Afifi et al., [@B3]
  41       Rolipram                                                                                                                Female Swiss albino mice       Low pathogenic strain   Chronic                   20 tissue cysts                                                            --                                                                                                                             Tissue injury scoring, brain cyst count, specific Ig G titers, TNF- α[^q^](#TN45){ref-type="table-fn"}, IFN- γ and IL-12 assays                                                                                             Significant reduction of TNFα (84.6%), IFN- γ (76.7%), IL-12 (71%)                                                                                        Partially effective                                     --                               Afifi and Al-Rabia, [@B2]
  42       Triclosan (TS) and triclosan-loaded liposomal nanoparticles                                                             Swiss strain Albino mice       RH HXGPRT (-)           Acute                     10^4^ tachyzoites                                                          150 mg/kg TS or 100 mg/kg TS liposomes                                                                                         Mice mortality, peritoneal, liver parasite burdens                                                                                                                                                                          Reduction in mice mortality, parasite burden                                                                                                              Effective                                               --                               El-Zawawy et al., [@B49]
  43       Sulfamethoxazole-trimethoprim (ST) associated with resveratrol                                                          Male Swiss albino mice         VEG strain              Chronic                   50 cysts containing bradyzoites                                            ST (groups B, F), free resveratrol (groups C,G) 0.5, 100 mg kg^−1^                                                             Cyst counts in the brain, and histopathology analyses                                                                                                                                                                       Combination was able to reduce the number of cysts in the brain, inflammatory infiltrates in the liver, prevented the occurrence of hepatocytes lesions   Effective                                               Sulfamethoxazole, trimethoprim   Bottari et al., [@B22]
  44       Ciprofloxacin derivatives (compounds 2, 4,5)                                                                            Female Swiss mice              RH                      Acute                     5 × 10^3^ tachyzoites i.p                                                  25, 50, 100, or 200 mg/kg/day a single oral dose                                                                               Survival rate, determine the serum levels of urea and creatinine kinase                                                                                                                                                     Increased mouse survival significantly, with 13--25% of mice surviving for up to 60 days post infection                                                   Effective                                               --                               Martins-Duarte et al., [@B89]
  45       Triclosan (TS), TS liposomal                                                                                            Swiss albino mice              ME49                    Chronic                   10 cysts                                                                   200, 120 mg/kg                                                                                                                 Mortality,brain parasite burden                                                                                                                                                                                             TS significant diminution in the parasite burden, great reduction in the infectivity power of *T.gondii* cysts                                            Effective                                               --                               El-Zawawy et al., [@B48]
  46       2-(Naphthalene-2-γlthiol)-1H Indole 2-(naphhalene-2-ylthio)-1H-indole                                                   BALB/c                         RH                      Acute                     2 × 10^6^ tachyzoites exposed to the concentrations of the compound i.p.   25--800 μM for 1.5 h                                                                                                           Surviving mice, stained by PI and analyzed by fluorescence-activated cell sorting (FACS)                                                                                                                                    The longevity of mice was dose dependent. Five mice out of group 400 μmol and 3 out of group 800 μmol showed immunization to the parasite                 Effective                                               --                               Asgari et al., [@B11]
  47       Propranolol                                                                                                             BALB/c                         RH                      Acute                     1 × 10^3^ tachyzoites i.p                                                  2, 3 mg/kg/day                                                                                                                 Parasite load determined                                                                                                                                                                                                    In the pre-treatment group, propranolol combined with pyrimethamine was more effective                                                                    Effective                                               Pyrimethamine                    Montazeri et al., [@B101]
  48       Aripiprazole                                                                                                            BALB/c                         Tehran strain           Chronic                   50 tissue cysts, i.p                                                       10, 20 mg/kg                                                                                                                   Cysts counted in smears prepared from brain homogenate by optical microscope                                                                                                                                                No significant difference between mean logarithms of brain cyst numbers of aripiprazole groups compared with control                                      No effective                                            --                               Saraei et al., [@B124]
  49       Pyrimethamine (PYR) and sulphadiazine (SDZ) combined with levamisole and echinacea                                      BALB/c                         RH                      30 days after treatment   10^5^ tachyzoite i.p                                                       PYR; 6.25, 12.5 SDZ; 100, 200 PYR, SDZ, levamisole; 2.5, echinacea; 130, 260 mg/kg/day oral treatment 24 h later for 10 days   Survival rates                                                                                                                                                                                                              Survival rate PYR+SDZ, and levamisole = 33.3% to 88.9%                                                                                                    Effective                                               Pyrimethamine, sulfadiazine      Köksal et al., [@B76]
  50       Miltefosine                                                                                                             Swiss albino mice              RH ME49                 Acute, chronic            2500 tachyzoites i.p 10 cysts orally                                       20 mg/kg for 5 days                                                                                                            Survival rates, tachyzoites count in the liver, spleen, cyst count and size in the brain ultra structural study, and histopathological study                                                                                Survival rate in acute = 30% Survival rate in chronic = 5%                                                                                                No effective in acute. Partially effective in chronic   Sulphadizine                     Eissa et al., [@B47]
                                                                                                                                                                                                                                                                                               20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                               60 days post infection for 15 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  51       Tetraoxanes                                                                                                             Female Swiss Webster           RH                      Acute                     10^2^ and 10^6^tachyzoite i.p                                              10 mg/kg/day, subcutaneously for 8 days                                                                                        Survival rates and pathohistological analysis                                                                                                                                                                               Survival rate = 20 %                                                                                                                                      Effective                                               --                               Opsenica et al., [@B108]
  52       Guanabenz                                                                                                               BALB/c                         ME49Prugniaud           Acute, chronic            10^4^ ME~49~or 10^6^ Pru tachyzoites, i.p                                  5 or 10 mg/kg repeated every 2 days                                                                                            Survival of mice, qPCR                                                                                                                                                                                                      Enhanced survival, reduces cyst burdens in chronically infected mice                                                                                      Effective                                               --                               Benmerzouga et al., [@B17]
  53       Fluphenazine and Thioridazine                                                                                           BALB/c                         Tehran strain           chronic                   20 tissue cysts i.p                                                        Thioridazine 10, 20, fluphenazine 0.06 mg/kg/ three days after inoculation for 3 weeks                                         The number of brain cysts                                                                                                                                                                                                   Drugs reduced the percent of cysts at higher dose compared to lower doses                                                                                 Effective, not significant                              Pyrimethamine                    Saraei et al., [@B123]
  54       Nitrofurantoin                                                                                                          Female ICR mice                RH                      Acute                     1 × 10^5^ tachyzoites                                                      20, 50, and 100 mg/kg, orally once/day for 4 days                                                                              The numbers of tachyzoites in the peritoneal cavity, Hematology and biochemical parameters                                                                                                                                  The inhibition rate = 44.7% hematology indicators and biochemical parameters reduced by nitrofurantoin significantly                                      Effective                                               Pyrimethamine                    Yeo et al., [@B150]
  55       Dextran sulfate                                                                                                         Pigs                           RH                      Acute                     1 × 10^6^ tachyzoites, intravenously                                       50--500 μg per head                                                                                                            host clinical, pathological, and immunological analyses                                                                                                                                                                     High-dose caused reversible hepatocellular degeneration of the liver                                                                                      Effective                                               .                                Kato et al., [@B73]
  56       Propranolol                                                                                                             BALB/c                         RH                      Acute, chronic            1 × 10^3^ tachyzoites i.p                                                  2, 3 mg/kg/day                                                                                                                 Parasite load determined by qPCR, and survival rate                                                                                                                                                                         Decreased the parasite load in brain, eye, and spleen tissues                                                                                             Effective                                               Pyrimethamine                    Montazeri et al., [@B102]
  57       Resveratrol and sulfamethoxazole-trimetropim                                                                            Male Swiss Webster             VEG                     Chronic                   50 cysts orally                                                            Oral doses of 0.5 and 100 mg/kg/day                                                                                            Counting brain cysts, tissue oxidant and antioxidant levels, and histopathology                                                                                                                                             A reduction on the number of cysts in the brain was observed                                                                                              Co-administration more effective                        Sulfamethoxazole-trimethoprim    Bottari et al., [@B21]
  58       Compound 22 of sulfur-containing linear bisphosphonates                                                                 Webster mice                   RH                      Acute                     20 or 100 or 5000 tachyzoites i.p                                          0.05, 0.1, 0.5, and 1 mg/kg of 22/ i.p. for 10 days                                                                            Survival rate                                                                                                                                                                                                               ED~50~= 0.02 mg/kg                                                                                                                                        Effective                                               .                                Szajnman et al., [@B137]
  59       Compound32 (TgCDPK1 inhibitor)                                                                                          Female CF-1 CBA/J              RH ME49                 Acute, chronic            less than 100 tachyzoites/mL                                               20 mg/kg for                                                                                                                   The numbers of tachyzoites in spleen, brain/ and the number of brain cysts                                                                                                                                                  Reducing infection in spleen and brain (99%, 95%) 88.7% reduction of brain cyst                                                                           Effective                                               .                                Vidadala et al., [@B144]
                                                                                                                                                                                                                                                                                               5 days/ oral gavage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                               30 mg/kg for 14 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

*2-hydroxy-3-(1\_-propen-3-phenyl)-1,4-naphthoquinone*.

*Indirect immunofluorescence antibody test*.

*Reverse transcription polymerase chain reaction*.

*Polymerase chain reaction*.

*Quantitative Polymerase chain reaction*.

*Fluconazole*.

*Itraconazole*.

*1-Hydroxy-2-Alkyl-4(1H) Quinolone*.

*6-trifluoromethyl-2-thiouracil*.

*3-\[{2-((E)-furan-2-ylmethylene) hydrazinyl} methylene\]-1, 3-dihydroindol-2-one*.

*Lipid peroxidation*.

*Glutathione-S-transferase*.

*Alanine aminotransferase*.

*Aspartate amino transferase*.

*Alkaline phosphatase*.

*Interferon gamma*.

*Tumor necrosis factor*.

Cell culture
------------

The cell cultures used in *in vitro* studies were mostly human foreskin fibroblast (HFF; 39 studies), LLCMK2 (12 studies), Vero (11 studies), Hela (6 studies), mouse macrophage cell line (J774A.1) (5 studies), and MRC-5 (2 studies; Table [3](#T3){ref-type="table"}).

Laboratory animals
------------------

*T. gondii* can infect most warm-blooded animals, and is studied in different animal models depending on the nature of the investigation (Szabo and Finney, [@B136]). The animal model used in studies was mostly mice (16 studies BALB/c and 19 studies Swiss-Webster). In murine models of acute toxoplasmosis, some medicines were protective even when administered at low dosages. But some drugs despite of their excellent *in vitro* activity were poorly protective in murine models with acute toxoplasmosis (Payne et al., [@B113]).

Diagnostic tests and evaluation methods
---------------------------------------

The present review outlines the results of *in vitro* screening methods including morphological assay, incorporation of \[3H\] uracil assay, plaque assays, enzyme-linked immunosorbent assay (ELISA), colorimetric micro titer assay (b-galactosidase assay), flow cytometric quantification assay, and cell viability assay. Numerous versions of fluorescent proteins have been expressed in *T. gondii* (Kim et al., [@B74]). The reporter genes used *in vitro* and *in vivo* studies were the green fluorescent protein (GFP) and yellow fluorescent protein (YFP). Parasites expressing fluorescent proteins can also be analyzed and sorted by flow cytometry. This technology used for drugs screening in 10 studies.

Details about the diagnostic methods and drug dosage under *in vivo* conditions are shown in Table [4](#T4){ref-type="table"}. Also, a comprehensive list of drugs/compounds evaluated against *T. gondii* with regard to IC~50~ is illustrated in Table [5](#T5){ref-type="table"}.

###### 

**A comprehensive list of drugs/compounds evaluated against ***T. gondii*** with regard to IC~**50**~**.

  **Drug**                                                                                                  **IC**~**50**~ **(**μ**M)**                                   **References**                                                                                        
  --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------ ------------------------------------
  Novel quinuclidine                                                                                        \+                                                                                                                                                                  Martins-Duarte et al., [@B93]
  Novel ferrocenic atovaquone derivatives                                                                   Atovaquone (PLK strain)                                       2d, 2e, 2f                                                                                            Baramee et al., [@B14]
  SAHA[^a^](#TN46){ref-type="table-fn"}, SBHA[^b^](#TN47){ref-type="table-fn"}, Scriptaid, Trichostatin A   Scriptaid                                                                                                                                                           Strobl et al., [@B132]
                                                                                                            Trichostatin A                                                                                                                                                      
                                                                                                            SAHA                                                                                                                                                                
                                                                                                            SBHA                                                                                                                                                                
  Pyridinylimidazoles SB203580 and SB202190                                                                 RWJ67657, (ME49 strain)                                       SB202190                                                         SB203580                             Wei et al., [@B145]
                                                                                                                                                                          SB203580                                                                                              
                                                                                                                                                                          RWJ68198, (ME49 strain)                                          RWJ68198, (RH strain)                
                                                                                                                                                                          RWJ67657, (RH strain)                                                                                 
  1-hydroxy-2-dodecyl-4(1H) quinolone                                                                       \+                                                                                                                                                                  Saleh et al., [@B122]
  Fluorine-containing aryloxyethyl thiocyanate derivatives                                                                                                                Compound 1, 3, 9                                                 Compound 10                          Liñares et al., [@B83]
  Novel diamidine analog                                                                                    \+                                                                                                                                                                  Leepin et al., [@B80]
  Pyrimethamine, sulfadiazine, atovaquone                                                                   \+                                                                                                                                                                  Meneceur et al., [@B96]
  Novel triazine JPC-2067-B                                                                                 \+                                                                                                                                                                  Mui et al., [@B105]
  2-alkylaminoethyl-1,1-bisphosphonic acids                                                                                                                               Compound 19                                                      Compound 14, 17                      Szajnman et al., [@B138]
  Itraconazole                                                                                              \+                                                                                                                                                                  Martins-Duarte Edos et al., [@B87]
  Thiolactomycin analog                                                                                                                                                   Compound 5, 6                                                    Compound 2                           Martins-Duarte et al., [@B90]
  Fluconazole (FLZ)                                                                                                                                                       FLZ (48 h)                                                       FLZ (24 h)                           Martins-Duarte et al., [@B91]
  1-Hydroxy-2-Alkyl-4(1H) Quinolone derivatives                                                             \+                                                                                                                                                                  Bajohr et al., [@B13]
  Haloperidol, clozapine, fluphenazine, trifluoperazine, thioridazine                                                                                                     \+                                                                                                    Goodwin et al., [@B61]
  Novel azasterols                                                                                          Compound 3 (48 h)                                             Compound 1 (48 h), 2, 3 (24 h)                                   Compound 1 (24 h)                    Martins-Duarte et al., [@B92]
  Endochin-like quinolones                                                                                  \+                                                                                                                                                                  Doggett et al., [@B41]
  Pterocarpanquinone                                                                                                                                                      \+                                                                                                    Portes Jde et al., [@B116]
  New naphthoquinones (QUI), an alkaloid                                                                    QUI-11                                                                                                                                                              Ferreira et al., [@B51]
                                                                                                            Liriodenine                                                                                                                                                         
  Di-cationic, pentamidine-analog                                                                           \+                                                                                                                                                                  Kropf et al., [@B77]
  Fuconazole combined with sulfadiazine and pyrimethamine                                                   Pyrimethamine                                                                                                                  \+                                   Martins-Duarte et al., [@B88]
  Antipsychotic drugs and valproate                                                                                                                                       Fluphenazine                                                     Zuclopenthixol                       Fond et al., [@B55]
                                                                                                                                                                          Thioridazine                                                                                          
  Fusidic acid                                                                                                                                                                                                                             \+                                   Payne et al., [@B113]
  Ivermectin and sulphadiazine                                                                              Ivermectin                                                                                                                     Sulphadiazine                        Bilgin et al., [@B19]
  Novel ruthenium complexes,(compounds 16 and 18)                                                           \+                                                                                                                                                                  Barna et al., [@B16]
  Auranofin                                                                                                 \+                                                                                                                                                                  Andrade et al., [@B6]
  6-Trifluoromethyl-2-thiouracil                                                                                                                                          \+                                                                                                    Choi et al., [@B30]
  200 drug-like, 200 probe-like compounds of Malaria Box                                                    MMV007791                                                     MMV007881                                                                                             Boyom et al., [@B23]
                                                                                                                                                                          MMV007363                                                                                             
                                                                                                                                                                          MMV006704                                                                                             
                                                                                                                                                                          MMV666095                                                                                             
                                                                                                                                                                          MMV020548                                                                                             
                                                                                                                                                                          MMV085203                                                                                             
  Quinoline derivatives                                                                                     8-Hydroxyquinoline, A 11, A14, A18, B11, B12, B15, B23, B24   A2-6, A12, A15---17, A23, B16, B22, B26, B27, B29, Chloroquine   Quinoline                            Kadri et al., [@B71]
                                                                                                                                                                                                                                           2-chloroquinoline                    
                                                                                                                                                                                                                                           5-Nitroqu                            
                                                                                                                                                                                                                                           Inoline Quinoline                    
                                                                                                                                                                                                                                           N-oxide hydrate A7, B18              
  Bumped Kinase Inhibitor 1294                                                                              \+                                                                                                                                                                  Doggett et al., [@B42]
  Salicylanilides                                                                                           3i, 3j, 7a, 14a, 14b                                                                                                                                                Fomovska et al., [@B54]
  Antiretroviral compounds                                                                                                                                                Atazanavir                                                       Fosamprenavir                        Monzote et al., [@B104]
                                                                                                                                                                          Ritonavir                                                        Nelfinavir                           
                                                                                                                                                                          Saquinavir                                                                                            
  Spiroindolone                                                                                                                                                           \+                                                                                                    Zhou et al., [@B155]
  Ciprofloxacin derivatives                                                                                 Compound 2, 5                                                 Compound 4                                                                                            Dubar et al., [@B43]
  Thiazolidin-4-one derivatives                                                                             12A                                                           27, 34 A                                                         36 A                                 D\'Ascenzio et al., [@B35]
  N6-benzyladenosine analog                                                                                                                                                                                                                Compound 11 e, g, j, n, o, q, u, v   Kim et al., [@B75]
  Naphthoquinone derivative                                                                                 LQB151 (48 h)                                                 LQB94                                                                                                 da Silva et al., [@B34]
                                                                                                                                                                          LQB151 (24 h)                                                                                         
                                                                                                                                                                          LQB150 (24, 48 h)                                                                                     
  Oryzalin analogs                                                                                          Compound 6a, h, i, 14a, 18a, b, c                             Compound 6b, g, j, I, n, 12                                      Compound 6m, 14b                     Endeshaw et al., [@B50]
  94 compounds                                                                                                                                                            \+                                                                                                    Dittmar et al., [@B40]
  6-(1,2,6,7-tetraoxaspiro\[7.11\] nonadec-4-yl)hexan-1-ol (N-251)                                                                                                        \+                                                                                                    Xin et al., [@B148]

*Suberoylanilide hydroxamic acid*.

*Suberic bishydroxamic acid*.

Discussion {#s4}
==========

The aim of this systematic review was to investigate the *in vitro* and *in vivo* effects of anti-*Toxoplasma* drugs and synthetic compounds, from 2006 to 2016. The current anti-*T. gondii* chemotherapy is deficient; as it is not well-tolerated by immunocompromised patients and cannot completely eradicate tissue cysts produced by the parasite (Rodriguez and Szajnman, [@B121]). Therefore, developing new, safe, effective, and well-tolerated drugs with novel mechanisms of action could be a global priority (Lai et al., [@B79]). An ideal drug for prophylaxis and/or treatment of toxoplasmosis would show effective penetration and concentration in the placenta, transplacental passage, parasiticidal properties vs. the different parasitic stages, penetration into cysts, and distribution in the main sites. No available drug fulfills these criteria (Derouin et al., [@B39]; Montoya and Liesenfeld, [@B103]).

Thus, the findings of the present systematic review article encourage and support more accurate investigations for future to select new anti-*Toxoplasma* drugs and strategies in designing new targets with specific activity against the parasite.

Activities of anti-*toxoplasma* clinically available drugs
----------------------------------------------------------

With growing parasite resistance to therapeutic drugs and in the absence of a vaccine, to increase the effectiveness of drugs, various changes have been made in construction of the clinically available medicines. Thus, the activity of new formulations of clinically available drugs against *T. gondii* should be evaluated to find alternative treatments for toxoplasmosis (da Cunha et al., [@B33]).

Interestingly, encapsulation of pyrimethamine improved the efficacy and tolerability of this drug against acute toxoplasmosis in mice and can be considered as an alternative for reducing the dose and side effects of pyrimethamine (Pissinate et al., [@B115]). Recently, researchers reported that computational analysis of biochemical differences between human and *T. gondii* dihydrofolate reductase enabled the design of inhibitors with both improved potency and selectivity against *T. gondii* (Welsch et al., [@B146]). El-Zawawy et al. reported that incorporating triclosan into in the lipid bilayer of liposomes allowed its use in lower doses, which in turn, reduced its biochemical adverse effects (El-Zawawy et al., [@B49]). In another study, sodium dodecyl sulfate (SDS)-coated atovaquone nanosuspensions (ANSs) considerably increased the therapeutic efficacy against experimentally reactivated and acquired toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. Accordingly, coating of ANSs with SDS may improve the treatment of toxoplasmic encephalitis and other cerebral diseases (Shubar et al., [@B127]).

Also, various studies showed that a number of drugs were investigated for the mechanisms of action summarized in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. One study discussing the metabolic differences between the host and the parasite noted that dihydrofolate reductase, isoprenoid pathway, and *T. gondii* histone deacetylase are promising molecular targets (Rodriguez and Szajnman, [@B121]).

Novel triazine JPC-2067-B (4, 6-diamino-1, 2-dihydro-2, 2-dimethyl-1-(3′(2-chloro-, 4-trifluoromethoxyphenoxy)propyloxy)-1, 3, 5-triazine), the anti-folate medicines, is highly effective against *T. gondii* with an IC~50~ of 0.02 μM, which is more efficacious than pyrimethamine and has *in vitro* cidal activity. Additionally, pro-drug JPC-2056 (1-(3′-(2-chloro-4-trifluoromethoxyphenyloxy) propyl oxy)-5-isopropylbiguanide) is effective *in vivo* when administered orally (Mui et al., [@B105]). Moreover, histone deacetylase is potentially a very important drug target in *T. gondii*, since scriptaid and trichostatin A had the highest effect against *T. gondii* tachyzoite proliferation with the IC~50~ of 0.039 and 0.041 μM, respectively (Strobl et al., [@B132]). For promising anti- *T. gondii* drugs/compounds, assessment of their ability to control parasite growth is a key step in drug development (McFarland et al., [@B95]).

A large number of research papers suggested that the apicoplast represents a potential drug target for new chemotherapy, as it is essential to the parasite and it is absent in host cells. Functions of the apicoplast include fatty acid synthesis, protein synthesis, DNA replication, electron transport, and heme biosynthesis (Yung and Lang-Unnasch, [@B152]). Some of the drugs evaluated against *T. gondii* are shown to act in the apicoplast such as thiolactomycin, triclosan (TS), azithromycin, fusidic acid, ciprofloxacin, and quinoline derivatives (Costa et al., [@B32]; Martins-Duarte et al., [@B90], [@B89]; Payne et al., [@B113]; Kadri et al., [@B71]; El-Zawawy et al., [@B49]).

In *T. gondii*, FAS-II enzymes are present in the apicoplast and are essential for its survival. The key enzyme in this process is the ENR enzyme, which is not found in mammals (Surolia and Surolia, [@B135]). This enzyme catalyzes the last reductive step of the type II FAS pathway. The TS, which inhibits type II FAS, significantly reduced mice mortality, parasite burden, as well as viability and infectivity of tachyzoites and cysts harvested from infected treated mice and their brains. Accordingly, TS is proved as an effective, promising, and safe preventive drug against acute and chronic murine toxoplasmosis. Liposomal formulation of TS enhanced its efficacy and allowed its use at a lower dose (Surolia and Surolia, [@B135]; El-Zawawy et al., [@B48],[@B49]). Among apicoplast pathways, DNA replication is an important potential chemotherapeutic target. Fluoroquinolones are the known DNA replication inhibitors that target prokaryotic type II topoisomerases (Collin et al., [@B31]). In two studies, researchers showed that derivatives of the antibiotic ciprofloxacin, a fluoroquinolone, are active against *T. gondii* tachyzoites both *in vitro* and *in vivo* (Neville et al., [@B106]). While all mice treated with ciprofloxacin died by day 10 post-infection, some mice treated with ciprofloxacin derivatives remained alive for at least 60 days, suggesting that ciprofloxacin derivatives cured *T. gondii* infection in treated mice (Dubar et al., [@B43]; Martins-Duarte et al., [@B89]).

Anti-*toxoplasma* activities of new synthetic compounds
-------------------------------------------------------

There are numerous reports on efficacy of many new synthetic compounds with a focus on identifying drug candidates with innovative and acceptable profiles against *T. gondii*. The anti-coccidial effect of 1-\[4-(4-nitrophenoxy) phenyl\] propane-1-one (NPPP), a synthetic compound, was studied both *in vitro* and *in vivo*. Treatment with NPPP showed anti-*Toxoplasma* activity *in vitro* with a lower EC~50~ value than pyrimethamine. In ICR mice infected with *T. gondii*, oral administration of NPPP for 4 days showed statistically significant anti-*Toxoplasma* activity with lower number of tachyzoites than those of the negative control (Choi et al., [@B29]).

In a study by Kadri et al. anti-*Toxoplasma* properties of 58 newly synthesized quinoline compounds were evaluated. A significant improvement in anti-*Toxoplasma* effect among quinoline derivatives was detected in B11, B12, B23, and B24. Among these compounds, B23 was the most effective compound with the IC~50~ value of \< 1 μM, displaying its anti-*Toxoplasma* effects and ability to cause the disappearance of the apicoplast (40--45% of the parasites lost their apicoplasts; Kadri et al., [@B71]).

In a study by Boyom et al. the strategy adopted was to repurpose the open access Malaria Box to identify chemical series active against *T. gondii*. The results showed that the most interesting compound was MMV007791, a piperazine acetamide, which has an IC~50~ of 0.19 μM. This compound is novel for its anti-*Toxoplasma* activity, and of course, further studies on the rates and mechanisms of compound action will elucidate these considerations (Boyom et al., [@B23]).

Tetraoxanes, anti-cancer molecules, were tested *in vivo* against *T. gondii*. Subcutaneous, administration of a 10 mg/kg/day dose of derivative 21, for 8 days allowed the survival of 20% of infected mice, demonstrating the high potential of tetraoxanes for the treatment of *T. gondii* (Opsenica et al., [@B108]).

In another study by Moine et al. researchers evaluated *in vitro* anti-*T. gondii* activity of 51 compounds with a biphenylimidazoazine scaffold. Eight of these compounds displayed highly potent activity against *T. gondii* growth *in vitro*, with 50% effective concentration (EC~50~) below 1 mM, without demonstrating cytotoxic effects on human fibroblastic cell at equivalent concentrations. However, these compounds have to be evaluated in animal models so as to confirm their *in vivo* activity (Moine et al., [@B99]).

Several pathways were characterized and shown to differ significantly from those of the mammalian host cells, thus, revealing an attractive area for therapeutic intervention. 1-Hydroxy-2-Alkyl-4 (1H) quinolone derivatives inhibit the fourth step of the essential *de novo* synthesis of pyrimidine, which uses ubiquinol reduction as an electron sink for dihydroorotate oxidation (Saleh et al., [@B122]). Also, newly synthesized bisphosphonates interfere with the mevanolate pathway, which leads to the synthesis of sterols and polyisoprenoid compounds that are important for parasite survival (Shubar et al., [@B128]).

Interestingly, Kamau et al. identified novel kinases that are integral to essential pathways, elucidating their mechanism of action and ultimately, identifying new drug targets (Kamau et al., [@B72]). In that study, 527 compounds were evaluated *in vitro;* also, they assessed the impact of the inhibitory compounds C1, C2, C3, and C5 in mouse models of toxoplasmosis. C2 was found quite effective in decreasing the parasite burden and increasing mice survival. These results should be considered with caution, since there are a number of factors are at play in whether a compound will be *in vivo* effective, such as solubility *in vivo*, access to different tissues, and host metabolic processes (Kamau et al., [@B72]). In a recent study, Dittmar et al. screened a collection of 1,120 compounds, 94 of which were blocked parasite replications with IC~50~ of \<5 μM. These data suggest that tamoxifen restricts *Toxoplasma* growth by inducing xenophagy or autophagic destruction of this parasite (Dittmar et al., [@B40]). According to a new study, *in silico* screening is useful, particularly in the identification of molecular targets in the laboratory. Fernandez et al. synthesized VAM2 compounds (7-nitroquinoxalin-2-ones), based on the design obtained from an *in silico* prediction with the software TOMOCOMD-CARDD. From the group of VAM2 compounds, Fernandez et al. chose VAM2-2 with an IC~50~ of 3.3 μM against *T. gondii*. However, more studies are required to evaluate its effect on the cysts formed by of the parasite and in animal models of toxoplasmosis (Fernández et al., [@B120]).

Activity of drugs, compounds, and combined therapy against cysts
----------------------------------------------------------------

An ideal drug against toxoplasmosis should not only be effective against the proliferative stage of the parasite but also exert dual activity against the tissue cyst stage and penetration into cysts (Benmerzouga et al., [@B17]). Currently, there is no approved therapy that eliminates the tissue cysts responsible for chronic infection (Innes, [@B67]). Derouin reported that among the drugs commonly used in humans, only atovaquone and azithromycin were found effective after long-term incubation. Besides, arpinocid-N-oxyde, an anticoccidial for veterinary use, was efficient at a high dosage (Derouin, [@B38]).

Recently, investigators have focused on guanabenz for *in vivo* studies, as guanabenz inhibitor of eIF2a dephosphorylation, is already an food and drug administration (FDA) approved drug and has excellent solubility with good penetration into the CNS. The results of that study show that guanabenz (5 mg/kg/day) not only protects mice against acute toxoplasmosis, but also reduces 69% of the number of brain cysts in chronically infected animals. This finding suggested that guanabenz can be repurposed into an effective antiparasitic with a unique ability to diminish tissue cysts in the brain (Benmerzouga et al., [@B17]).

Another study showed that miltefosine had no efficacy in controlling acute toxoplasmosis after 5 days of treatment; however, a 15-day treatment against the established chronic stage led to a 78% reduction of cysts in the brain. Additionally, the remaining cysts were noticeably smaller upon microscopic examination, suggesting that the drug effectively penetrates the blood-brain barrier, and that extension of treatment time may produce greater effects (Eissa et al., [@B47]).

In another study by Maubon et al. FR235222 and its derivatives were identified as new lead compounds for use against acute and chronic toxoplasmosis both *in vitro* and *in vivo*. *In vivo* experiments indicated that FR235222, as a histone deacetylase inhibitor, is able to access the bradyzoites within the cyst. The ability of FR235222 to permeate the membrane wall is a major advantage for crossing the blood-brain barrier and CNS tissue, where *Toxoplasma* cysts are located. This opens a promising way to develop drugs that are selective against *Toxoplasma* and those that have sterilizing activity, especially in patients with cysts, who are at risk for reactivating acute toxoplasmosis (patients with HIV infection, hematological malignancies, or transplantation). Still, effectiveness of FR235222 against chronically infected mice remains to be directly demonstrated *in vivo* (Maubon et al., [@B94]).

In a new study Vidadala et al. identified compounds 32 (*T. gondii* calcium-dependent protein kinase 1 inhibitor) a promising lead for the development of a new antitoxoplasmosis therapy. Compounds 32 is CNS-penetrant and highly effective in acute and latent mouse models of *T. gondii* infection, significantly reducing brain cysts by 88.7% (Vidadala et al., [@B144]).

Many studies reported anti- *Toxoplasma* effects of different drugs combination with novel compounds. The compound 2-hydroxy-3-(1′-propen-3-phenyl)-1, 4-naphthoquinone (PHNQ6), (50 mg/kg/day) combined with sulfadiazine showed reduction or elimination of brain cysts *in vivo* (Ferreira et al., [@B52]). In another study that coadministered spiramycin and metronidazole, spiramycin, did not reach effective concentrations in the brain due to the presence of the efflux transporters multidrug-resistant protein 2, and P-glycoprotein. Metronidazole increased brain penetration of spiramycin, causing a significant reduction of *T. gondii* brain cysts, with potential clinical translatability for chronic toxoplasmosis treatment. According to the reports, combination therapy leads to faster recovery, less relapse, lower doses of drugs, and fewer side effects of the disease. Furthermore, such combinations are highly promising to develop a drug that is able to eliminate the cyst stage of the parasite, and thus, efficiently impairs relapse of the disease (Chew et al., [@B28]; Martins-Duarte et al., [@B88]).

Activity of drugs against congenital toxoplasmosis
--------------------------------------------------

In pregnant women, current toxoplasmosis treatment is based on the administration of spiramycin or a drug combination such as sulphadiazine-pyrimethamine-folinic acid (SPFA) in cases of confirmed fetal infection. However, these drugs are not well-tolerated and present many adverse effects due to their toxic effects to the host (Degerli et al., [@B37]).

Degerli et al. evaluated the effectiveness of azithromycin, artemisia annua infusion, spiramycin, and SPFA in Calomys callosus, such as model of congenital toxoplasmosis. The results demonstrated that the treatment of pregnant *C. callosus* with azithromycin was effective for inhibiting the vertical transmission of *T. gondii* ME49 strain, suggesting that it may be an alternative drug of choice for the treatment of congenital infection, since it is able to inhibit fetal infection and offers new perspectives for the treatment of congenital toxoplasmosis. Azithromycin is one of the new generation macrolides with numerous advantages. Mechanism of action of azithromycin is based on the inhibition of protein synthesis in both *T. gondii* tachyzoite and bradyzoite stages (Degerli et al., [@B37]), but it may present limited effectiveness against *T. gondii*, requiring high drug concentrations (Costa et al., [@B32]). In another study, Oz et al. reported that combined atovaquone and diclazuril therapy is a novel synergistic prophylactic and therapeutic approach to fetal maternal toxoplasmosis (Oz, [@B109]). Atovaquone, an inhibitor of mitochondrial electron-transport processes, is an FDA-approved toxoplasmosis therapy but not for use in congenital toxoplasmosis treatment (Oz, [@B109]). Another compound, diclazuril, and its related benzeneacetonitriles have long been used in the treatment and prevention of poultry and livestock coccidiosis. In addition, it is known to be a safe compound at therapeutic dose levels (Assis et al., [@B12]).

Adverse effects of drugs
------------------------

However, anti-*Toxoplasma* effects of drugs/compounds were reported in many trials, but prednisolone increased the number of tachyzoites and bradyzoites in immunosuppressed infected mice (Puvanesuaran et al., [@B117]). In addition, betamethasone can escalate the invasion of tachyzoites, in cell culture. It could be suggested that patients under prolonged use of betamethasone and prednisolone should be protected against *T. gondii* infection. Also, if individuals receiving betamethasone are infected with *T. gondii*, interferon-gamma may be used to reduce the invasion of tachyzoites (Ghaffarifar et al., [@B59]).

Conclusions {#s5}
===========

As current chemotherapy against toxoplasmosis is still not satisfactory, the development of well-tolerated and safe specific immunoprophylaxis in relaxing the need of dependence on chemotherapeutics is a highly valuable goal for global disease control. Immunotherapeutics strategies for improving toxoplasmosis control could either be a vaccine which would induce strong protective immunity against toxoplasmosis, or passive immunization in cases of disease recrudescence. However, with the increasing number of high-risk individuals, such as immunocompromised patients, and absence of a proper vaccine, continued efforts are necessary for the development of novel treatment options against *T. gondii*. Some of the novel compounds reviewed here may represent good starting points for the discovery of effective new drugs. In further bioinformatic and *in silico* studies are needed in order to identify new potential toxoplasmicidal drugs.
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